<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11679989</article-id><article-id pub-id-type="doi">10.3390/vaccines12121321</article-id><article-id pub-id-type="publisher-id">vaccines-12-01321</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>The Impact of Vaccinations Against Respiratory Infections on the Prognosis in Heart Failure Patients</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0003-9617-0273</contrib-id><name><surname>Jankowiak</surname><given-names>Berenika</given-names></name><xref rid="af1-vaccines-12-01321" ref-type="aff">1</xref><xref rid="c1-vaccines-12-01321" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Wleklik</surname><given-names>Marta</given-names></name><xref rid="af2-vaccines-12-01321" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Rosiek-Biegus</surname><given-names>Marta</given-names></name><xref rid="af3-vaccines-12-01321" ref-type="aff">3</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Tripp</surname><given-names>Ralph A.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-12-01321"><label>1</label>Institute of Heart Diseases, Wroclaw Medical University, 50-556 Wroclaw, Poland</aff><aff id="af2-vaccines-12-01321"><label>2</label>Division of Research Methodology, Department of Nursing, Faculty of Nursing and Midwifery, Wroclaw Medical University, 50-556 Wroclaw, Poland; <email>marta.wleklik@umw.edu.pl</email></aff><aff id="af3-vaccines-12-01321"><label>3</label>Institute of Internal Diseases, Wroclaw Medical University, 50-556 Wroclaw, Poland; <email>marta.rosiek-biegus@umw.edu.pl</email></aff><author-notes><corresp id="c1-vaccines-12-01321"><label>*</label>Correspondence: <email>berenika.jankowiak@student.umw.edu.pl</email>; Tel.: +48-783-014-880</corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>12</volume><issue>12</issue><elocation-id>1321</elocation-id><history><date date-type="received"><day>15</day><month>10</month><year>2024</year></date><date date-type="rev-recd"><day>22</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>23</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Heart failure (HF) affects 64 million people worldwide and is one of the most prevalent causes of hospitalization in adults. Infection is believed to be one of the potential triggers that may facilitate HF decompensation and the need for hospitalization. Therefore, it seems crucial to safeguard against such a situation. Vaccinations seem to be a very reasonable option. However, this remains an underutilized solution among HF patients. This review investigates the impact of available vaccinations, including influenza, COVID-19, pneumococcal, and RSV, on prognosis in specific HF populations only, as there are pathophysiological reasons to believe that this population of patients may benefit the most from the intervention. It will provide information about the safety profile of these vaccines and summarize the available evidence on their impact on hard clinical outcomes. In summary, this article will discuss the impact of preventive vaccinations against seasonal infections in the HF population.</p></abstract><kwd-group><kwd>heart failure</kwd><kwd>influenza vaccination</kwd><kwd>pneumococcal vaccination</kwd><kwd>COVID-19 vaccination</kwd><kwd>RSV vaccination</kwd><kwd>cardiovascular diseases</kwd></kwd-group><funding-group><award-group><funding-source>Wroc&#x00142;aw Medical University</funding-source></award-group><funding-statement>This research was funded by Wroc&#x00142;aw Medical University.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-12-01321"><title>1. Introduction</title><p>Heart failure (HF) is a multifaceted syndrome affecting 64 million people worldwide [<xref rid="B1-vaccines-12-01321" ref-type="bibr">1</xref>] and is the leading cause of hospitalization for individuals over 65 years of age [<xref rid="B2-vaccines-12-01321" ref-type="bibr">2</xref>,<xref rid="B3-vaccines-12-01321" ref-type="bibr">3</xref>,<xref rid="B4-vaccines-12-01321" ref-type="bibr">4</xref>]. The pathophysiology of the disease is complex and involves the background neurohormonal overactivity, compromised immune function, and chronic inflammatory state [<xref rid="B5-vaccines-12-01321" ref-type="bibr">5</xref>,<xref rid="B6-vaccines-12-01321" ref-type="bibr">6</xref>,<xref rid="B7-vaccines-12-01321" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-12-01321" ref-type="bibr">8</xref>]. This not only affects the cardiovascular system but influences the function of other organs and systems, thereby further impacting daily functioning and significantly lowering the health-related quality of life (HRQoL) [<xref rid="B9-vaccines-12-01321" ref-type="bibr">9</xref>] of patients. This leads to numerous hospitalizations and a shortening of life [<xref rid="B8-vaccines-12-01321" ref-type="bibr">8</xref>,<xref rid="B10-vaccines-12-01321" ref-type="bibr">10</xref>,<xref rid="B11-vaccines-12-01321" ref-type="bibr">11</xref>,<xref rid="B12-vaccines-12-01321" ref-type="bibr">12</xref>,<xref rid="B13-vaccines-12-01321" ref-type="bibr">13</xref>].</p><p>In the general population, infections can cause thrombosis or exacerbation of atherosclerosis, which can result in myocardial infarction. The perfect example is COVID-19, which can cause dysfunction of endothelium and activation of platelets, which in turn leads to hypercoagulability and excessive inflammation state, which has prothrombotic potential. This pathophysiology can also trigger arrhythmia [<xref rid="B14-vaccines-12-01321" ref-type="bibr">14</xref>]. Influenza and COVID-19 increase the risk of acute myocardial infarction [<xref rid="B15-vaccines-12-01321" ref-type="bibr">15</xref>,<xref rid="B16-vaccines-12-01321" ref-type="bibr">16</xref>,<xref rid="B17-vaccines-12-01321" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-12-01321" ref-type="bibr">18</xref>]. Infection is one of the potential trigger mechanisms that may disturb the fragile homeostasis of HF pathophysiology, which may lead to episodes of overt HF decompensation. On the other hand, the direct viral infection affecting the cardiomyocytes may lead to myocarditis and life-threatening clinical scenarios [<xref rid="B19-vaccines-12-01321" ref-type="bibr">19</xref>,<xref rid="B20-vaccines-12-01321" ref-type="bibr">20</xref>,<xref rid="B21-vaccines-12-01321" ref-type="bibr">21</xref>].</p><p>Moreover, most HF patients are frail; the disease itself, as well as co-morbidities and advanced age, make the population even more frail and prone to any infection-related complications [<xref rid="B22-vaccines-12-01321" ref-type="bibr">22</xref>,<xref rid="B23-vaccines-12-01321" ref-type="bibr">23</xref>,<xref rid="B24-vaccines-12-01321" ref-type="bibr">24</xref>]. Based on those assumptions, it is hypothesized that it&#x02019;s important for patients affected by the disease to be vaccinated&#x02014;especially prior to the infection season [<xref rid="B25-vaccines-12-01321" ref-type="bibr">25</xref>,<xref rid="B26-vaccines-12-01321" ref-type="bibr">26</xref>]. All of these factors pose a potential cause of HF development and progression in some scenarios. Infections can also pose significant dangers to a patient&#x02019;s already exhausted body, potentially leading to severe conditions, such as sepsis or septic shock [<xref rid="B27-vaccines-12-01321" ref-type="bibr">27</xref>].</p><p>A study conducted by Alon and Stein et al. showed that patients with HF hospitalized due to respiratory tract infections or sepsis/bacteremia have a much higher 30-day mortality rate than patients hospitalized for other infections [<xref rid="B28-vaccines-12-01321" ref-type="bibr">28</xref>]. The same study also showed that upper respiratory tract infections are one of the most common reasons for hospitalization in HF patients, accounting for as much as 52.6% of hospitalization causes in this population [<xref rid="B28-vaccines-12-01321" ref-type="bibr">28</xref>]. It is interesting, therefore, that the vaccination rate among the HF population is relatively low [<xref rid="B29-vaccines-12-01321" ref-type="bibr">29</xref>].</p><p>All those facts set the stage for this article, in which we present a review of the available data summarizing the impact of respiratory infection prevention by influenza, COVID-19, respiratory syncytial virus (RSV), and Streptococcus pneumoniae vaccinations on the outcomes of the HF populations. We will also present the safety profile of these vaccinations.</p></sec><sec sec-type="results" id="sec2-vaccines-12-01321"><title>2. Results</title><sec id="sec2dot1-vaccines-12-01321"><title>2.1. Influenza</title><sec id="sec2dot1dot1-vaccines-12-01321"><title>2.1.1. The Risk Related to Influenza Infection</title><p>The influenza virus, belonging to Orthomyxoviridae, causes acute respiratory tract infection with secondary complications, including myocarditis, pericarditis, acute kidney injury, secondary bacterial pneumonia, exacerbation of chronic diseases, such as COPD or HF, as well as Reye syndrome or Guillain&#x02013;Barr&#x000e9; syndrome. Influenza affects people in all age groups and is associated with high mortality, especially among higher-risk groups like elderly patients or those with severe comorbidities. Due to point mutations (antigenic drift), there are annual epidemics, creating the need for seasonal updates in the vaccines against this virus [<xref rid="B30-vaccines-12-01321" ref-type="bibr">30</xref>,<xref rid="B31-vaccines-12-01321" ref-type="bibr">31</xref>,<xref rid="B32-vaccines-12-01321" ref-type="bibr">32</xref>].</p><p>Clinical research by Panhwar et al. revealed that influenza infection is linked to a higher risk of in-hospital morbidity and in-hospital mortality among HF patients [<xref rid="B33-vaccines-12-01321" ref-type="bibr">33</xref>].</p></sec><sec id="sec2dot1dot2-vaccines-12-01321"><title>2.1.2. The Reported Benefit of Influenza Vaccination in HF Population</title><p>In a study by Loeb et al., conducted in Asia, the Middle East, and Africa, analyzing the impact of influenza vaccination in reducing adverse vascular events in 5129 HF patients, the comparison was made between the effect of this vaccine and all-cause hospitalizations, pneumonia, all-cause death, cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and HF hospitalization. This study was divided into the infectious and non-infectious seasons. During the non-infectious season, differences between the study group receiving vaccination and the controls receiving placebo were not significant, with a lower number of pneumonia cases in vaccinated individuals compared to controls. During the infectious season, a reduction in the number of all-cause deaths, cardiovascular deaths, and pneumonia was observed in vaccinated patients. The vaccinated cohort had the highest reduction in pneumonia [<xref rid="B34-vaccines-12-01321" ref-type="bibr">34</xref>].</p><p>A meta-analysis by Poudel et al. [<xref rid="B35-vaccines-12-01321" ref-type="bibr">35</xref>] conducted on studies involving 16,751 patients showed a significant reduction in mortality risk in HF patients vaccinated against influenza within a year of vaccination (HR, 0.69; 95% CI, 0.51&#x02013;0.87), as pictured in <xref rid="vaccines-12-01321-t001" ref-type="table">Table 1</xref>, index 2. The same meta-analysis involving 9055 patients showed a lower risk of hospitalization among vaccinated patients compared to the unvaccinated group (HR, 0.62; 95% CI, 0.00&#x02013;1.23), which was, however, statistically not significant.</p><p>The study by Modin et al. conducted on 134,048 individuals also showed a decrease in mortality among HF patients vaccinated annually compared to unvaccinated individuals by 19%, both in the case of all-cause death risk (HR, 0.82; 95% CI, 0.81&#x02013;0.84, <italic toggle="yes">p</italic> &#x0003c; 0.001), and in the case of cardiovascular death (HR, 0.82; 95% CI, 0.81&#x02013;0.84, <italic toggle="yes">p</italic> &#x0003c; 0.001). Vaccination in the HF population was also associated with a lower risk of hospitalization due to influenza or pneumonia (HR, 0.96; 95% CI, 0.93&#x02013;0.98, <italic toggle="yes">p</italic> = 0.002) [<xref rid="B36-vaccines-12-01321" ref-type="bibr">36</xref>].</p><p>Kopel et al., after analyzing vaccinated compared to not-vaccinated HF patients assigned to the HFSIS (the heart failure survey in Israel) registry, showed that in-hospital and 1-year mortality rates were HR, 0.71; 95% CI 0.42&#x02013;1.18, <italic toggle="yes">p</italic> = 0.19 and HR, 0.81; 95% CI 0.66&#x02013;0.99, <italic toggle="yes">p</italic> = 0.04, respectively. Particular significance was found in the observed risk of 4-year mortality, which amounted to HR, 0.83; 95% CI, 0.73&#x02013;0.95, <italic toggle="yes">p</italic> = 0.006 [<xref rid="B37-vaccines-12-01321" ref-type="bibr">37</xref>].</p><p>The PARADIGM-HF-Trial with 8099 participants showed us that influenza vaccination is related with reduced risk for all-cause death (HR, 0.81; 95% CI 0.67&#x02013;0.97, <italic toggle="yes">p</italic> = 0.015). It also gave us information about the percentage of vaccinated residents for each country&#x02014;the data is presented in <xref rid="vaccines-12-01321-t002" ref-type="table">Table 2</xref> [<xref rid="B38-vaccines-12-01321" ref-type="bibr">38</xref>].</p><p>The meta-analysis of Gupta et al. was focused on reducing adverse events by influenza vaccine. It demonstrated that the risk of all-cause cardiovascular-related mortality was significantly reduced, but all-cause hospitalization was higher among vaccinated patients with heart failure [<xref rid="B41-vaccines-12-01321" ref-type="bibr">41</xref>].</p><p>In the clinical trial presented by Vardeny et al. [<xref rid="B44-vaccines-12-01321" ref-type="bibr">44</xref>], influenza vaccines&#x02014;high dose trivalent and standard dose quadrivalent&#x02014;were considered separately among patients with high-risk cardiovascular diseases. The comparison showed that the high dose trivalent vaccine did not significantly reduce the risk of all-cause death and cardiopulmonary hospitalizations.</p><p>In <xref rid="vaccines-12-01321-t002" ref-type="table">Table 2</xref>, we presented a comparison of influenza vaccination coverage across specific countries [<xref rid="B38-vaccines-12-01321" ref-type="bibr">38</xref>,<xref rid="B39-vaccines-12-01321" ref-type="bibr">39</xref>]. We compared the two extremes presented in the table&#x02014;Poland and Spain&#x02014;based on the statistical data we gathered. In Poland, in 2021, the prevalence was 2.63%, with as many as 205,000 hospitalizations due to heart failure (HF); while in Spain, the prevalence in 2019 was close to 2%, with an incidence rate of 2.78 per 1000. This difference was influenced not only by vaccination coverage but by various other factors, such as differences in the age structure of the populations studied and genetic differences. However, considering the aforementioned research, we can infer that vaccination is significant in protecting HF patients [<xref rid="B43-vaccines-12-01321" ref-type="bibr">43</xref>,<xref rid="B45-vaccines-12-01321" ref-type="bibr">45</xref>].</p></sec><sec id="sec2dot1dot3-vaccines-12-01321"><title>2.1.3. The Safety Data of Influenza Vaccination</title><p>The safety profile of the influenza vaccine also needs to be pointed out. There is no increased risk of side effects, such as Guillain&#x02013;Barr&#x000e9; syndrome, seizures, encephalitis, or anaphylaxis following vaccination in HF population [<xref rid="B46-vaccines-12-01321" ref-type="bibr">46</xref>]. The vaccination is recommended directly in current ESC guidelines, class IIa, level of evidence B [<xref rid="B9-vaccines-12-01321" ref-type="bibr">9</xref>]. Importantly, although vaccination is recommended to reduce the risk of HF hospitalizations, it is also mentioned as an effective intervention to prevent the development of HF. No specific recommendation is made with respect to the type of vaccine [<xref rid="B47-vaccines-12-01321" ref-type="bibr">47</xref>].</p></sec></sec><sec id="sec2dot2-vaccines-12-01321"><title>2.2. COVID-19</title><sec id="sec2dot2dot1-vaccines-12-01321"><title>2.2.1. The Risk Related to COVID-19 Infection in Heart Failure Population</title><p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a pathogen from the Coronaviridae family, first registered in China in 2019. This contagious virus has caused millions of confirmed widespread cases and deaths [<xref rid="B48-vaccines-12-01321" ref-type="bibr">48</xref>,<xref rid="B49-vaccines-12-01321" ref-type="bibr">49</xref>]. Patients with conditions such as heart failure are at an especially elevated risk of morbidity and mortality caused by this pathogen [<xref rid="B50-vaccines-12-01321" ref-type="bibr">50</xref>,<xref rid="B51-vaccines-12-01321" ref-type="bibr">51</xref>,<xref rid="B52-vaccines-12-01321" ref-type="bibr">52</xref>,<xref rid="B53-vaccines-12-01321" ref-type="bibr">53</xref>]. COVID-19 itself may also result in cardiac disorder, presenting diverse ventricular dysfunctions (including myocarditis) [<xref rid="B51-vaccines-12-01321" ref-type="bibr">51</xref>].</p><p>The vast majority of patients experience this infection mildly, but some prone patients with severe illnesses, such as those with HF [<xref rid="B50-vaccines-12-01321" ref-type="bibr">50</xref>], may develop what is known as a cytokine storm, an excessive immune system response that can result in severe respiratory failure [<xref rid="B54-vaccines-12-01321" ref-type="bibr">54</xref>].</p><p>There have also been reported cases of pericarditis, myocardial infarction, Takotsubo cardiomyopathy, and arrhythmias developing as a result of COVID-19 infection, as well as cardiogenic shock related to the infection, which may lead to myocardial dysfunction themselves [<xref rid="B19-vaccines-12-01321" ref-type="bibr">19</xref>,<xref rid="B55-vaccines-12-01321" ref-type="bibr">55</xref>,<xref rid="B56-vaccines-12-01321" ref-type="bibr">56</xref>,<xref rid="B57-vaccines-12-01321" ref-type="bibr">57</xref>,<xref rid="B58-vaccines-12-01321" ref-type="bibr">58</xref>,<xref rid="B59-vaccines-12-01321" ref-type="bibr">59</xref>,<xref rid="B60-vaccines-12-01321" ref-type="bibr">60</xref>,<xref rid="B61-vaccines-12-01321" ref-type="bibr">61</xref>,<xref rid="B62-vaccines-12-01321" ref-type="bibr">62</xref>]. Paradoxically, lifestyle changes related to the pandemic and lockdowns decreased emergency admissions, and a lower risk of HF hospitalizations, compared to the pre-pandemic timeframe [<xref rid="B63-vaccines-12-01321" ref-type="bibr">63</xref>,<xref rid="B64-vaccines-12-01321" ref-type="bibr">64</xref>,<xref rid="B65-vaccines-12-01321" ref-type="bibr">65</xref>,<xref rid="B66-vaccines-12-01321" ref-type="bibr">66</xref>,<xref rid="B67-vaccines-12-01321" ref-type="bibr">67</xref>,<xref rid="B68-vaccines-12-01321" ref-type="bibr">68</xref>,<xref rid="B69-vaccines-12-01321" ref-type="bibr">69</xref>]. Moreover, the self-isolation of many patients and in-depth knowledge/fear regarding the risks of infection may also influence the lower rates of hospitalizations.</p><p>On the other hand, we may argue that this phenomenon is more complex than that. The other possible explanation for the lower emergency admission rates may be related to the assumption that patients (especially those at the highest risk) ignored severe conditions (like clinical signs of decongestion or chest pain) to prevent hospitalization, as the highest risk of acquiring the COVID infection was in the hospital. This was associated with higher out-of-hospital mortality, worse performance indicators, and higher in-hospital mortality (as patients admitted were, in general, in more advanced stages of the disease) [<xref rid="B70-vaccines-12-01321" ref-type="bibr">70</xref>].</p></sec><sec id="sec2dot2dot2-vaccines-12-01321"><title>2.2.2. The Reported Benefit of COVID-19 Vaccination in HF Population</title><p>The study by Sinder-Pedersen et al., based on Danish registries included patients (each cohort consisting of 50,893 patients), compared the risk of 90-day all-cause death, 90-day in-hospital admission for HF, 90-day risk of venous thromboembolism, 90-day risk of myocarditis, and 90-day risk of pneumonia in HF patients vaccinated against COVID-19 (data from 2021) with the risk in HF patients unvaccinated against COVID-19 (data from 2019). The risk difference was &#x02212;0.33% [95% CI, &#x02212;0.52% to &#x02212;0.15%] for all-cause death, favoring vaccinated individuals; the difference in the risk of HF decompensation within 90 days was not significant and amounted to 0.02% [95% CI, &#x02212;0.11% to 0.15%]; however, if the patient was hospitalized within 90 days, the risk difference of HF decompensation was &#x02212;1.91% [95% CI, &#x02212;5.25% to 1.43%] with an advantage for vaccinated individuals. The risk difference for pneumonia was significantly lower in vaccinated individuals &#x02212;0.64% [95% CI, &#x02212;0.81% to &#x02212;0.49%]. The risk difference for venous thromboembolism was minimal and amounted to non-significant &#x02212;0.02% [95% CI, &#x02212;0.05% to 0.01%] in favor of vaccinated individuals (<xref rid="vaccines-12-01321-t001" ref-type="table">Table 1</xref>) [<xref rid="B42-vaccines-12-01321" ref-type="bibr">42</xref>].</p><p>Studies indirectly support the benefit of COVID-19 vaccination in relation to HF. This vaccination reduces the risk of cardiovascular outcomes due to COVID-19 infection, such as myocardial infarction [<xref rid="B16-vaccines-12-01321" ref-type="bibr">16</xref>,<xref rid="B17-vaccines-12-01321" ref-type="bibr">17</xref>], which can trigger HF development and decompensation.</p></sec><sec id="sec2dot2dot3-vaccines-12-01321"><title>2.2.3. The Safety Data of COVID-19 Vaccination</title><p>It has been shown that mRNA vaccines are associated with an increased risk of myocarditis and pericarditis, especially in males aged 12&#x02013;17 years. The pathophysiology of myocarditis and pericarditis related to COVID-19 (as well as other viruses) is poorly understood. It is hypothesized that some COVID-19-related myocarditis involves direct viral damage to cardiomyocytes through SARS-CoV-2 binding to ACE2 receptors, triggering apoptosis and necrosis. The infection induces a strong inflammatory response, including a cytokine storm (e.g., IL-6, IL-1&#x003b2;, TNF-&#x003b1;), endothelial dysfunction, and microvascular thrombosis, which exacerbate myocardial injury. Autoimmune mechanisms and subsequent fibrosis lead to long-term cardiac remodeling, reducing contractility, and increasing the risk of heart failure and arrhythmias.</p><p>Long COVID, on the other hand, refers to a range of persistent symptoms and complications that occur months after the acute infection. Its pathophysiology is multifactorial, involving chronic inflammation, immune dysregulation, and endothelial dysfunction, leading to tissue damage and impaired recovery. Viral persistence in certain tissues may also contribute to ongoing symptoms. Additionally, mitochondrial dysfunction and altered autonomic regulation (dysautonomia) are thought to play a role in fatigue, cardiovascular instability, and neurological manifestations. Notwithstanding, the vast majority of patients experience mild infection and do not need admission to the hospital; negligence of these conditions is dangerous. They can occur as patients, usually young men, with pain in the chest, heart palpitations, or shortness of breath during the first 7 days after vaccination [<xref rid="B52-vaccines-12-01321" ref-type="bibr">52</xref>]. These vaccines may also lead to such adverse events as lymphadenopathy or facial nerve palsy [<xref rid="B15-vaccines-12-01321" ref-type="bibr">15</xref>,<xref rid="B56-vaccines-12-01321" ref-type="bibr">56</xref>,<xref rid="B57-vaccines-12-01321" ref-type="bibr">57</xref>,<xref rid="B58-vaccines-12-01321" ref-type="bibr">58</xref>,<xref rid="B59-vaccines-12-01321" ref-type="bibr">59</xref>,<xref rid="B61-vaccines-12-01321" ref-type="bibr">61</xref>,<xref rid="B62-vaccines-12-01321" ref-type="bibr">62</xref>,<xref rid="B63-vaccines-12-01321" ref-type="bibr">63</xref>,<xref rid="B64-vaccines-12-01321" ref-type="bibr">64</xref>,<xref rid="B65-vaccines-12-01321" ref-type="bibr">65</xref>,<xref rid="B66-vaccines-12-01321" ref-type="bibr">66</xref>,<xref rid="B67-vaccines-12-01321" ref-type="bibr">67</xref>,<xref rid="B68-vaccines-12-01321" ref-type="bibr">68</xref>,<xref rid="B69-vaccines-12-01321" ref-type="bibr">69</xref>,<xref rid="B70-vaccines-12-01321" ref-type="bibr">70</xref>,<xref rid="B71-vaccines-12-01321" ref-type="bibr">71</xref>,<xref rid="B72-vaccines-12-01321" ref-type="bibr">72</xref>,<xref rid="B73-vaccines-12-01321" ref-type="bibr">73</xref>,<xref rid="B74-vaccines-12-01321" ref-type="bibr">74</xref>]. Autopsy studies have shown a causal relationship between vaccination and the abovementioned complications [<xref rid="B66-vaccines-12-01321" ref-type="bibr">66</xref>,<xref rid="B75-vaccines-12-01321" ref-type="bibr">75</xref>,<xref rid="B76-vaccines-12-01321" ref-type="bibr">76</xref>].</p><p>However, the study by Barda et al. [<xref rid="B77-vaccines-12-01321" ref-type="bibr">77</xref>] showed that, while the post-vaccination risk is significantly increased (RR, 3.24; 95% CI, 1.55&#x02013;12.44), it is much lower than the risk after COVID-19 infection (RR, 18.28; 95% CI, 3.95&#x02013;25.12). It is notable that a complete vaccination course provides protection not only for HF patients, but for patients undergoing treatment for myocardial infarction [<xref rid="B78-vaccines-12-01321" ref-type="bibr">78</xref>]. Be that as it may, being simultaneously vaccinated and having post-infection immunization appear to predispose patients with myocardial infarction with ST elevation to evolving cardiovascular conditions, such as cardiogenic shock or severe heart failure [<xref rid="B20-vaccines-12-01321" ref-type="bibr">20</xref>]. The protection and effectiveness of the vaccination can be elevated using boosters [<xref rid="B53-vaccines-12-01321" ref-type="bibr">53</xref>].</p><p>The most commonly used vaccines were two-dose Pfizer&#x02013;BioNTech (BNT162b2), Oxford&#x02013;AstraZeneca (AZD1222), Moderna (mRNA-1273), and single-dose Johnson &#x00026; Johnson (Ad26.COV2.S), with subsequent booster doses being desirable [<xref rid="B79-vaccines-12-01321" ref-type="bibr">79</xref>]. Furthermore, a meta-analysis from 2023 indicates that the number of serious adverse events in older individuals after this vaccination is very low despite the occurrence of post-vaccination symptoms, such as pain or fever [<xref rid="B80-vaccines-12-01321" ref-type="bibr">80</xref>].</p><p>Cases, such as immune thrombotic thrombocytopenia (TTS), cerebral venous sinus thrombosis, VTE, TIA and stroke, acute myocardial infarction, arrhythmia, and large-vessel vasculitis, have been reported following COVID-19 vaccination, but the risk is disproportionately low compared to the risk following the infection itself [<xref rid="B55-vaccines-12-01321" ref-type="bibr">55</xref>,<xref rid="B81-vaccines-12-01321" ref-type="bibr">81</xref>,<xref rid="B82-vaccines-12-01321" ref-type="bibr">82</xref>,<xref rid="B83-vaccines-12-01321" ref-type="bibr">83</xref>]. Similarly, notwithstanding confirmed myocarditis and pericarditis following COVID-19 vaccination cases, the protective role occurred to overcome the risks, especially among the elderly [<xref rid="B84-vaccines-12-01321" ref-type="bibr">84</xref>].</p></sec></sec><sec id="sec2dot3-vaccines-12-01321"><title>2.3. Pneumococcal Vaccination</title><sec id="sec2dot3dot1-vaccines-12-01321"><title>2.3.1. The Risk Related to Pneumococcal Infection</title><p>Streptococcus pneumoniae is a gram-positive bacteria that is a common cause of many pneumococcal infections, such as pneumonia, otitis media, meningitis, and sepsis. It is a serious threat, especially for children, the elderly, and immunocompromised patients [<xref rid="B85-vaccines-12-01321" ref-type="bibr">85</xref>]. The direct data on the HF population is scarce, but based on the HF pathophysiology and the fact that the HF population is more likely to develop infection-related complications, it is highly advisable for HF patients to prevent those pathogens [<xref rid="B86-vaccines-12-01321" ref-type="bibr">86</xref>,<xref rid="B87-vaccines-12-01321" ref-type="bibr">87</xref>].</p></sec><sec id="sec2dot3dot2-vaccines-12-01321"><title>2.3.2. The Reported Benefit of Pneumococcal Vaccination</title><p>Pneumococcal vaccination, similar to influenza vaccination, is recommended in the recent ESC guidelines for managing heart failure (class IIa, level of evidence B) [<xref rid="B9-vaccines-12-01321" ref-type="bibr">9</xref>]. However, prospective randomized controlled trials are lacking to directly confirm the impact of this vaccination on patients with heart failure [<xref rid="B88-vaccines-12-01321" ref-type="bibr">88</xref>]. Available studies are not unanimous, so this cannot be conclusively stated. The meta-analyses by Marra et al. and Marques Antunes et al. demonstrated that pneumococcal vaccination was associated with a reduction in the risk of cardiovascular events, all-cause mortality, and myocardial infarction, in the former, and all-cause mortality in patients at very high cardiovascular risk, in the latter [<xref rid="B89-vaccines-12-01321" ref-type="bibr">89</xref>,<xref rid="B90-vaccines-12-01321" ref-type="bibr">90</xref>]. However, it is important to note that the populations examined in the meta-analyses were not limited to heart failure.</p><p>In the huge observational study by Bhatt et al. analyzing 313,761 patients from late 2012 to early 2017 (from the Get With The Guidelines&#x02013;HF Registry), it was shown that pneumococcal and/or influenza vaccination does not affect the clinical outcomes of HF patients [<xref rid="B40-vaccines-12-01321" ref-type="bibr">40</xref>]. This may represent a true lack of the protective effect of the pneumococcal vaccination in the HF population or the high competing risk in the population that significantly reduces the observed benefit of the intervention.</p></sec><sec id="sec2dot3dot3-vaccines-12-01321"><title>2.3.3. The Safety Data of Pneumococcal Vaccination</title><p>PCV13 and PPSV23 vaccines, most used against pneumococci, are safe for adults, including those over 65. The most reported side effects were headache, myalgia, arthralgia, pain at the injection site, and fatigue [<xref rid="B91-vaccines-12-01321" ref-type="bibr">91</xref>,<xref rid="B92-vaccines-12-01321" ref-type="bibr">92</xref>,<xref rid="B93-vaccines-12-01321" ref-type="bibr">93</xref>].</p></sec></sec><sec id="sec2dot4-vaccines-12-01321"><title>2.4. RSV Vaccination</title><sec id="sec2dot4dot1-vaccines-12-01321"><title>2.4.1. The Risk Related to RSV Infection</title><p>Respiratory syncytial virus (RSV), belonging to the Paramyxoviridae family, is commonly known for childhood infections. Like pneumococci, it also poses a threat to adults with reduced immunity and the elderly, especially those with cardiovascular diseases such as HF [<xref rid="B94-vaccines-12-01321" ref-type="bibr">94</xref>]. RSV infection is associated with an increased risk of acute heart failure, and patients with chronic HF are at a heightened risk for RSV infection [<xref rid="B95-vaccines-12-01321" ref-type="bibr">95</xref>,<xref rid="B96-vaccines-12-01321" ref-type="bibr">96</xref>].</p><p>In a cross-sectional study of more than 6200 adults (&#x0003e;50 years old) observed over five RSV seasons, nearly one-quarter experienced an acute cardiac event (most frequently AHF). The risk of severe outcomes was nearly twice as high in patients with acute cardiac events compared with patients who did not experience an acute cardiac event [<xref rid="B95-vaccines-12-01321" ref-type="bibr">95</xref>].</p><p>Hospitalization due to RSV infection may be associated with or complicated by outcomes such as acute respiratory illness, arrhythmias, myocardial infarction, acute heart failure, Intensity Care Unit admission, receipt of invasive mechanical ventilation, or in-hospital death [<xref rid="B97-vaccines-12-01321" ref-type="bibr">97</xref>]. In the study conducted by Loubet et al., 19% of patients also presented acute heart failure during hospitalization for RSV [<xref rid="B98-vaccines-12-01321" ref-type="bibr">98</xref>]. New diagnostic techniques may lead to significant improvements in the identification of the infection [<xref rid="B96-vaccines-12-01321" ref-type="bibr">96</xref>].</p></sec><sec id="sec2dot4dot2-vaccines-12-01321"><title>2.4.2. The Benefit of RSV Vaccination</title><p>The Arexvy (GSK) and Abrysvo (Pfizer) vaccines have been available for individuals aged &#x02265;60 years only since 2023 and are not currently included in ESC recommendations, as little is known about them in the context of HF.</p></sec><sec id="sec2dot4dot3-vaccines-12-01321"><title>2.4.3. The Safety Data of RSV Vaccination</title><p>The study by Biegus et al. [<xref rid="B99-vaccines-12-01321" ref-type="bibr">99</xref>] examined the early safety profile of simultaneous vaccination with Arexvy and Vaxigrip Tetra vaccines. In this prospective study, 105 patients received both vaccines, and only 6% of patients reported symptoms that interfered with their daily functioning. There were also no deaths or hospitalizations due to HF decompensation or any other serious adverse events within a week after vaccination.</p></sec></sec></sec><sec sec-type="conclusions" id="sec3-vaccines-12-01321"><title>3. Conclusions</title><p>Vaccination against respiratory system infections in HF patients remains a topic that needs to be discovered further. Notwithstanding the fact that HF patients are at high risk of both infections and their complications, there are relatively few prospective, randomized studies that clearly address their impact on HF prognosis. Large-scale, high-quality data are extremely needed; as important as the effect of vaccinations is, it is probably difficult to demonstrate, due to large numbers of competing risks in HF cohorts. Thus, the &#x0201c;pure&#x0201d; protective effect of the intervention is blunted and may be lost, especially in small samples.</p><p>Influenza vaccination is one of the best-studied in the HF population, and therefore, it is recommended in many sources, with its benefits being evident. The early safety profile of this vaccine has also been investigated in combination with simultaneous vaccination against RSV and influenza and appears promising. It would be particularly desirable to conduct RCTs on the impact of pneumococcal and RSV vaccinations in individuals with HF, as the definitive evidence in the group is missing.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization: B.J.; validation: B.J. and M.R.-B.; data curation: B.J.; writing&#x02014;original draft preparation: B.J., M.R.-B., and M.W.; writing&#x02014;review and editing: B.J., M.W, and M.R.-B.; supervision: M.R.-B.; project administration: M.R.-B. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><p>HF&#x02014;heart failure; RSV&#x02014;respiratory syncytial virus; HRQoL&#x02014;health-related quality of life; COPD&#x02014;chronic obstructive pulmonary disease; HFrEF&#x02014;heart failure with restricted ejection fraction; HfmrEF&#x02014;heart failure with mild restricted ejection fraction; HFpEF&#x02014;heart failure with preserved ejection fraction.</p></glossary><ref-list><title>References</title><ref id="B1-vaccines-12-01321"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shahim</surname><given-names>B.</given-names></name>
<name><surname>Kapelios</surname><given-names>C.J.</given-names></name>
<name><surname>Savarese</surname><given-names>G.</given-names></name>
<name><surname>Lund</surname><given-names>L.H.</given-names></name>
</person-group><article-title>Global Public Health Burden of Heart Failure: An Updated Review</article-title><source>Card. Fail. Rev.</source><year>2023</year><volume>9</volume><fpage>e11</fpage><pub-id pub-id-type="doi">10.15420/cfr.2023.05</pub-id><pub-id pub-id-type="pmid">37547123</pub-id>
</element-citation></ref><ref id="B2-vaccines-12-01321"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>D&#x000ed;ez-Villanueva</surname><given-names>P.</given-names></name>
<name><surname>Alfonso</surname><given-names>F.</given-names></name>
</person-group><article-title>Heart failure in the elderly</article-title><source>J. Geriatr. Cardiol.</source><year>2016</year><volume>13</volume><fpage>115</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.11909/j.issn.1671-5411.2016.02.009</pub-id><pub-id pub-id-type="pmid">27168735</pub-id>
</element-citation></ref><ref id="B3-vaccines-12-01321"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Salah</surname><given-names>H.M.</given-names></name>
<name><surname>Minhas</surname><given-names>A.M.K.</given-names></name>
<name><surname>Khan</surname><given-names>M.S.</given-names></name>
<name><surname>Khan</surname><given-names>S.U.</given-names></name>
<name><surname>Ambrosy</surname><given-names>A.P.</given-names></name>
<name><surname>Blumer</surname><given-names>V.</given-names></name>
<name><surname>Vaduganathan</surname><given-names>M.</given-names></name>
<name><surname>Greene</surname><given-names>S.J.</given-names></name>
<name><surname>Pandey</surname><given-names>A.</given-names></name>
<name><surname>Fudim</surname><given-names>M.</given-names></name>
</person-group><article-title>Trends and characteristics of hospitalizations for heart failure in the United States from 2004 to 2018</article-title><source>ESC Heart Fail.</source><year>2022</year><volume>9</volume><fpage>947</fpage><lpage>952</lpage><pub-id pub-id-type="doi">10.1002/ehf2.13823</pub-id><pub-id pub-id-type="pmid">35098700</pub-id>
</element-citation></ref><ref id="B4-vaccines-12-01321"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Huang</surname><given-names>Z.</given-names></name>
<name><surname>Liang</surname><given-names>Y.</given-names></name>
<name><surname>Zhao</surname><given-names>X.</given-names></name>
<name><surname>Aobuliksimu</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>B.</given-names></name>
<name><surname>He</surname><given-names>Y.</given-names></name>
<name><surname>Kang</surname><given-names>Y.</given-names></name>
<name><surname>Huang</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>Q.</given-names></name>
<etal/>
</person-group><article-title>Five-year mortality of heart failure with preserved, mildly reduced, and reduced ejection fraction in a 4880 Chinese cohort</article-title><source>ESC Heart Fail.</source><year>2022</year><volume>9</volume><fpage>2336</fpage><lpage>2347</lpage><pub-id pub-id-type="doi">10.1002/ehf2.13921</pub-id><pub-id pub-id-type="pmid">35437939</pub-id>
</element-citation></ref><ref id="B5-vaccines-12-01321"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zymli&#x00144;ski</surname><given-names>R.</given-names></name>
<name><surname>Sokolski</surname><given-names>M.</given-names></name>
<name><surname>Biegus</surname><given-names>J.</given-names></name>
<name><surname>Siwo&#x00142;owski</surname><given-names>P.</given-names></name>
<name><surname>Nawrocka-Millward</surname><given-names>S.</given-names></name>
<name><surname>Sokolska</surname><given-names>J.M.</given-names></name>
<name><surname>Dudkowiak</surname><given-names>M.</given-names></name>
<name><surname>Marciniak</surname><given-names>D.</given-names></name>
<name><surname>Todd</surname><given-names>J.</given-names></name>
<name><surname>Jankowska</surname><given-names>E.A.</given-names></name>
<etal/>
</person-group><article-title>Multi-organ dysfunction/injury on admission identifies acute heart failure patients at high risk of poor outcome</article-title><source>Eur. J. Heart Fail.</source><year>2018</year><volume>21</volume><fpage>744</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.1002/ejhf.1378</pub-id><pub-id pub-id-type="pmid">30561066</pub-id>
</element-citation></ref><ref id="B6-vaccines-12-01321"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pandhi</surname><given-names>P.</given-names></name>
<name><surname>ter Maaten</surname><given-names>J.M.</given-names></name>
<name><surname>Anker</surname><given-names>S.D.</given-names></name>
<name><surname>Ng</surname><given-names>L.L.</given-names></name>
<name><surname>Metra</surname><given-names>M.</given-names></name>
<name><surname>Samani</surname><given-names>N.J.</given-names></name>
<name><surname>Lang</surname><given-names>C.C.</given-names></name>
<name><surname>Dickstein</surname><given-names>K.</given-names></name>
<name><surname>de Boer</surname><given-names>R.A.</given-names></name>
<name><surname>van Veldhuisen</surname><given-names>D.J.</given-names></name>
<etal/>
</person-group><article-title>Pathophysiologic Processes and Novel Biomarkers Associated with Congestion in Heart Failure</article-title><source>JACC Heart Fail.</source><year>2022</year><volume>10</volume><fpage>623</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1016/j.jchf.2022.05.013</pub-id><pub-id pub-id-type="pmid">36049813</pub-id>
</element-citation></ref><ref id="B7-vaccines-12-01321"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Biegus</surname><given-names>J.</given-names></name>
<name><surname>Niewinski</surname><given-names>P.</given-names></name>
<name><surname>Josiak</surname><given-names>K.</given-names></name>
<name><surname>Kulej</surname><given-names>K.</given-names></name>
<name><surname>Ponikowska</surname><given-names>B.</given-names></name>
<name><surname>Nowak</surname><given-names>K.</given-names></name>
<name><surname>Zymlinski</surname><given-names>R.</given-names></name>
<name><surname>Ponikowski</surname><given-names>P.</given-names></name>
</person-group><article-title>Pathophysiology of Advanced Heart Failure: What Knowledge Is Needed for Clinical Management?</article-title><source>Heart Fail. Clin.</source><year>2021</year><volume>17</volume><fpage>519</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1016/j.hfc.2021.06.001</pub-id><pub-id pub-id-type="pmid">34511202</pub-id>
</element-citation></ref><ref id="B8-vaccines-12-01321"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thapa</surname><given-names>A.</given-names></name>
<name><surname>Kang</surname><given-names>J.</given-names></name>
<name><surname>Chung</surname><given-names>M.L.</given-names></name>
<name><surname>Wu</surname><given-names>J.-R.</given-names></name>
<name><surname>Latimer</surname><given-names>A.</given-names></name>
<name><surname>Lennie</surname><given-names>T.A.</given-names></name>
<name><surname>Lin</surname><given-names>C.-Y.</given-names></name>
<name><surname>Thompson</surname><given-names>J.H.</given-names></name>
<name><surname>Cha</surname><given-names>G.</given-names></name>
<name><surname>Moser</surname><given-names>D.K.</given-names></name>
</person-group><article-title>Perceived Control, Functional Status, Depressive Symptoms, and Anxiety: Mediating and Moderating Influences on Health-Related Quality of Life in Patients With Heart Failure</article-title><source>J. Cardiovasc. Nurs.</source><year>2024</year><pub-id pub-id-type="doi">10.1097/JCN.0000000000001100</pub-id></element-citation></ref><ref id="B9-vaccines-12-01321"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McDonagh</surname><given-names>T.A.</given-names></name>
<name><surname>Metra</surname><given-names>M.</given-names></name>
<name><surname>Adamo</surname><given-names>M.</given-names></name>
<name><surname>Gardner</surname><given-names>R.S.</given-names></name>
<name><surname>Baumbach</surname><given-names>A.</given-names></name>
<name><surname>B&#x000f6;hm</surname><given-names>M.</given-names></name>
<name><surname>Burri</surname><given-names>H.</given-names></name>
<name><surname>Butler</surname><given-names>J.</given-names></name>
<name><surname>&#x0010c;elutkien&#x00117;</surname><given-names>J.</given-names></name>
<name><surname>Chioncel</surname><given-names>O.</given-names></name>
<etal/>
</person-group><article-title>2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC</article-title><source>Eur. Heart J.</source><year>2023</year><volume>44</volume><fpage>3627</fpage><lpage>3639</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehad195</pub-id><pub-id pub-id-type="pmid">37622666</pub-id>
</element-citation></ref><ref id="B10-vaccines-12-01321"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carlsson</surname><given-names>K.S.</given-names></name>
<name><surname>Faurby</surname><given-names>M.</given-names></name>
<name><surname>Nilsson</surname><given-names>K.</given-names></name>
<name><surname>Wolden</surname><given-names>M.L.</given-names></name>
</person-group><article-title>Cardiovascular events, mortality, early retirement and costs in &#x0003e;50,000 persons with chronic heart failure in Sweden</article-title><source>ESC Heart Fail.</source><year>2023</year><volume>11</volume><fpage>54</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1002/ehf2.14480</pub-id><pub-id pub-id-type="pmid">37814495</pub-id>
</element-citation></ref><ref id="B11-vaccines-12-01321"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nakamaru</surname><given-names>R.</given-names></name>
<name><surname>Shiraishi</surname><given-names>Y.</given-names></name>
<name><surname>Sandhu</surname><given-names>A.T.</given-names></name>
<name><surname>Heidenreich</surname><given-names>P.A.</given-names></name>
<name><surname>Shoji</surname><given-names>S.</given-names></name>
<name><surname>Kohno</surname><given-names>T.</given-names></name>
<name><surname>Takei</surname><given-names>M.</given-names></name>
<name><surname>Nagatomo</surname><given-names>Y.</given-names></name>
<name><surname>Nakano</surname><given-names>S.</given-names></name>
<name><surname>Kohsaka</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Cardiovascular vs. non-cardiovascular deaths after heart failure hospitalization in young, older, and very old patients</article-title><source>ESC Heart Fail.</source><year>2022</year><volume>10</volume><fpage>673</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1002/ehf2.14245</pub-id><pub-id pub-id-type="pmid">36436825</pub-id>
</element-citation></ref><ref id="B12-vaccines-12-01321"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Leszek</surname><given-names>P.</given-names></name>
<name><surname>Wa&#x0015b;</surname><given-names>D.</given-names></name>
<name><surname>Bartolik</surname><given-names>K.</given-names></name>
<name><surname>Witczak</surname><given-names>K.</given-names></name>
<name><surname>Kleinork</surname><given-names>A.</given-names></name>
<name><surname>Maruszewski</surname><given-names>B.</given-names></name>
<name><surname>Bruka&#x00142;o</surname><given-names>K.</given-names></name>
<name><surname>Rolska-W&#x000f3;jcik</surname><given-names>P.</given-names></name>
<name><surname>Celi&#x00144;ska-Spodar</surname><given-names>M.</given-names></name>
<name><surname>Hryniewiecki</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Burden of hospitalizations in newly diagnosed heart failure patients in Poland: Real world population based study in years 2013&#x02013;2019</article-title><source>ESC Heart Fail.</source><year>2022</year><volume>9</volume><fpage>1553</fpage><lpage>1563</lpage><pub-id pub-id-type="doi">10.1002/ehf2.13900</pub-id><pub-id pub-id-type="pmid">35322601</pub-id>
</element-citation></ref><ref id="B13-vaccines-12-01321"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wideqvist</surname><given-names>M.</given-names></name>
<name><surname>Rosengren</surname><given-names>A.</given-names></name>
<name><surname>Schaufelberger</surname><given-names>M.</given-names></name>
<name><surname>Pivodic</surname><given-names>A.</given-names></name>
<name><surname>Fu</surname><given-names>M.</given-names></name>
</person-group><article-title>Ten year age- and sex-specific temporal trends in incidence and prevalence of heart failure in V&#x000e4;stra G&#x000f6;taland, Sweden</article-title><source>ESC Heart Fail.</source><year>2022</year><volume>9</volume><fpage>3931</fpage><lpage>3941</lpage><pub-id pub-id-type="doi">10.1002/ehf2.14103</pub-id><pub-id pub-id-type="pmid">35957620</pub-id>
</element-citation></ref><ref id="B14-vaccines-12-01321"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nishiga</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>D.W.</given-names></name>
<name><surname>Han</surname><given-names>Y.</given-names></name>
<name><surname>Lewis</surname><given-names>D.B.</given-names></name>
<name><surname>Wu</surname><given-names>J.C.</given-names></name>
</person-group><article-title>COVID-19 and cardiovascular disease: From basic mechanisms to clinical perspectives</article-title><source>Nat. Rev. Cardiol.</source><year>2020</year><volume>17</volume><fpage>543</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1038/s41569-020-0413-9</pub-id><pub-id pub-id-type="pmid">32690910</pub-id>
</element-citation></ref><ref id="B15-vaccines-12-01321"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fountoulaki</surname><given-names>K.</given-names></name>
<name><surname>Tsiodras</surname><given-names>S.</given-names></name>
<name><surname>Polyzogopoulou</surname><given-names>E.</given-names></name>
<name><surname>Olympios</surname><given-names>C.</given-names></name>
<name><surname>Parissis</surname><given-names>J.</given-names></name>
</person-group><article-title>Beneficial Effects of Vaccination on Cardiovascular Events: Myocardial Infarction, Stroke, Heart Failure</article-title><source>Cardiology</source><year>2018</year><volume>141</volume><fpage>98</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1159/000493572</pub-id><pub-id pub-id-type="pmid">30428464</pub-id>
</element-citation></ref><ref id="B16-vaccines-12-01321"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>Y.-E.</given-names></name>
<name><surname>Huh</surname><given-names>K.</given-names></name>
<name><surname>Park</surname><given-names>Y.-J.</given-names></name>
<name><surname>Peck</surname><given-names>K.R.</given-names></name>
<name><surname>Jung</surname><given-names>J.</given-names></name>
</person-group><article-title>Association Between Vaccination and Acute Myocardial Infarction and Ischemic Stroke After COVID-19 Infection</article-title><source>JAMA</source><year>2022</year><volume>328</volume><fpage>887</fpage><lpage>889</lpage><pub-id pub-id-type="doi">10.1001/jama.2022.12992</pub-id><pub-id pub-id-type="pmid">35867050</pub-id>
</element-citation></ref><ref id="B17-vaccines-12-01321"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Whiteley</surname><given-names>W.N.</given-names></name>
<name><surname>Ip</surname><given-names>S.</given-names></name>
<name><surname>Cooper</surname><given-names>J.A.</given-names></name>
<name><surname>Bolton</surname><given-names>T.</given-names></name>
<name><surname>Keene</surname><given-names>S.</given-names></name>
<name><surname>Walker</surname><given-names>V.</given-names></name>
<name><surname>Denholm</surname><given-names>R.</given-names></name>
<name><surname>Akbari</surname><given-names>A.</given-names></name>
<name><surname>Omigie</surname><given-names>E.</given-names></name>
<name><surname>Hollings</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England</article-title><source>PLoS Med.</source><year>2022</year><volume>19</volume><elocation-id>e1003926</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.1003926</pub-id><pub-id pub-id-type="pmid">35192597</pub-id>
</element-citation></ref><ref id="B18-vaccines-12-01321"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Boer</surname><given-names>A.R.</given-names></name>
<name><surname>Riezebos-Brilman</surname><given-names>A.</given-names></name>
<name><surname>van Hout</surname><given-names>D.</given-names></name>
<name><surname>van Mourik</surname><given-names>M.S.</given-names></name>
<name><surname>R&#x000fc;mke</surname><given-names>L.W.</given-names></name>
<name><surname>de Hoog</surname><given-names>M.L.</given-names></name>
<name><surname>Vaartjes</surname><given-names>I.</given-names></name>
<name><surname>Bruijning-Verhagen</surname><given-names>P.C.</given-names></name>
</person-group><article-title>Influenza Infection and Acute Myocardial Infarction</article-title><source>NEJM &#x000c9;vid.</source><year>2024</year><volume>3</volume><fpage>EVIDoa2300361</fpage><pub-id pub-id-type="doi">10.1056/EVIDoa2300361</pub-id><pub-id pub-id-type="pmid">38916418</pub-id>
</element-citation></ref><ref id="B19-vaccines-12-01321"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Smet</surname><given-names>M.</given-names></name>
<name><surname>Fierens</surname><given-names>J.</given-names></name>
<name><surname>Vanhulle</surname><given-names>L.</given-names></name>
<name><surname>Weygaerde</surname><given-names>Y.V.</given-names></name>
<name><surname>Malfait</surname><given-names>T.</given-names></name>
<name><surname>Devos</surname><given-names>D.</given-names></name>
<name><surname>Haerynck</surname><given-names>F.</given-names></name>
<name><surname>Gevaert</surname><given-names>S.</given-names></name>
</person-group><article-title>SARS-CoV-2-related Multisystem Inflammatory Syndrome in Adult complicated by myocarditis and cardiogenic shock</article-title><source>ESC Heart Fail.</source><year>2022</year><volume>9</volume><fpage>4315</fpage><lpage>4324</lpage><pub-id pub-id-type="doi">10.1002/ehf2.14126</pub-id><pub-id pub-id-type="pmid">36043434</pub-id>
</element-citation></ref><ref id="B20-vaccines-12-01321"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kiblboeck</surname><given-names>D.</given-names></name>
<name><surname>Klingel</surname><given-names>K.</given-names></name>
<name><surname>Genger</surname><given-names>M.</given-names></name>
<name><surname>Traxler</surname><given-names>S.</given-names></name>
<name><surname>Braunsteiner</surname><given-names>N.</given-names></name>
<name><surname>Steinwender</surname><given-names>C.</given-names></name>
<name><surname>Kellermair</surname><given-names>J.</given-names></name>
</person-group><article-title>Myocarditis following mRNA COVID-19 vaccination: Call for endomyocardial biopsy</article-title><source>ESC Heart Fail.</source><year>2022</year><volume>9</volume><fpage>1996</fpage><lpage>2002</lpage><pub-id pub-id-type="doi">10.1002/ehf2.13791</pub-id><pub-id pub-id-type="pmid">35194974</pub-id>
</element-citation></ref><ref id="B21-vaccines-12-01321"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arrigo</surname><given-names>M.</given-names></name>
<name><surname>Jessup</surname><given-names>M.</given-names></name>
<name><surname>Mullens</surname><given-names>W.</given-names></name>
<name><surname>Reza</surname><given-names>N.</given-names></name>
<name><surname>Shah</surname><given-names>A.M.</given-names></name>
<name><surname>Sliwa</surname><given-names>K.</given-names></name>
<name><surname>Mebazaa</surname><given-names>A.</given-names></name>
</person-group><article-title>Acute heart failure</article-title><source>Nat. Rev. Dis. Prim.</source><year>2020</year><volume>6</volume><fpage>16</fpage><pub-id pub-id-type="doi">10.1038/s41572-020-0151-7</pub-id><pub-id pub-id-type="pmid">32139695</pub-id>
</element-citation></ref><ref id="B22-vaccines-12-01321"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hamada</surname><given-names>T.</given-names></name>
<name><surname>Kubo</surname><given-names>T.</given-names></name>
<name><surname>Kawai</surname><given-names>K.</given-names></name>
<name><surname>Nakaoka</surname><given-names>Y.</given-names></name>
<name><surname>Yabe</surname><given-names>T.</given-names></name>
<name><surname>Furuno</surname><given-names>T.</given-names></name>
<name><surname>Yamada</surname><given-names>E.</given-names></name>
<name><surname>Kitaoka</surname><given-names>H.</given-names></name>
</person-group><article-title>Kochi YOSACOI study Frailty interferes with the guideline-directed medical therapy in heart failure patients with reduced ejection fraction</article-title><source>ESC Heart Fail.</source><year>2022</year><volume>10</volume><fpage>223</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1002/ehf2.14163</pub-id><pub-id pub-id-type="pmid">36193578</pub-id>
</element-citation></ref><ref id="B23-vaccines-12-01321"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bruno</surname><given-names>R.R.</given-names></name>
<name><surname>Uzel</surname><given-names>R.</given-names></name>
<name><surname>Spieker</surname><given-names>M.</given-names></name>
<name><surname>Datz</surname><given-names>C.</given-names></name>
<name><surname>Oehler</surname><given-names>D.</given-names></name>
<name><surname>B&#x000f6;nner</surname><given-names>F.</given-names></name>
<name><surname>Kelm</surname><given-names>M.</given-names></name>
<name><surname>Hoppichler</surname><given-names>F.</given-names></name>
<name><surname>Jung</surname><given-names>C.</given-names></name>
<name><surname>Wernly</surname><given-names>B.</given-names></name>
</person-group><article-title>The impact of gender and frailty on the outcome of older patients with functional mitral regurgitation</article-title><source>ESC Heart Fail.</source><year>2023</year><volume>10</volume><fpage>2948</fpage><lpage>2954</lpage><pub-id pub-id-type="doi">10.1002/ehf2.14478</pub-id><pub-id pub-id-type="pmid">37489061</pub-id>
</element-citation></ref><ref id="B24-vaccines-12-01321"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abe</surname><given-names>T.</given-names></name>
<name><surname>Jujo</surname><given-names>K.</given-names></name>
<name><surname>Maeda</surname><given-names>D.</given-names></name>
<name><surname>Saito</surname><given-names>K.</given-names></name>
<name><surname>Ogasahara</surname><given-names>Y.</given-names></name>
<name><surname>Saito</surname><given-names>K.</given-names></name>
<name><surname>Saito</surname><given-names>H.</given-names></name>
<name><surname>Iwata</surname><given-names>K.</given-names></name>
<name><surname>Konishi</surname><given-names>M.</given-names></name>
<name><surname>Kitai</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>The interaction between physical frailty and prognostic impact of heart failure medication in elderly patients</article-title><source>ESC Heart Fail.</source><year>2023</year><volume>10</volume><fpage>1698</fpage><lpage>1705</lpage><pub-id pub-id-type="doi">10.1002/ehf2.14114</pub-id><pub-id pub-id-type="pmid">36824014</pub-id>
</element-citation></ref><ref id="B25-vaccines-12-01321"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Palazzuoli</surname><given-names>A.</given-names></name>
<name><surname>Metra</surname><given-names>M.</given-names></name>
<name><surname>Collins</surname><given-names>S.P.</given-names></name>
<name><surname>Adamo</surname><given-names>M.</given-names></name>
<name><surname>Ambrosy</surname><given-names>A.P.</given-names></name>
<name><surname>Antohi</surname><given-names>L.E.</given-names></name>
<name><surname>Ben Gal</surname><given-names>T.</given-names></name>
<name><surname>Farmakis</surname><given-names>D.</given-names></name>
<name><surname>Gustafsson</surname><given-names>F.</given-names></name>
<name><surname>Hill</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Heart failure during the COVID-19 pandemic: Clinical, diagnostic, management, and organizational dilemmas</article-title><source>ESC Heart Fail.</source><year>2022</year><volume>9</volume><fpage>3713</fpage><lpage>3736</lpage><pub-id pub-id-type="doi">10.1002/ehf2.14118</pub-id><pub-id pub-id-type="pmid">36111511</pub-id>
</element-citation></ref><ref id="B26-vaccines-12-01321"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dennert</surname><given-names>R.</given-names></name>
<name><surname>Crijns</surname><given-names>H.J.</given-names></name>
<name><surname>Heymans</surname><given-names>S.</given-names></name>
</person-group><article-title>Acute viral myocarditis</article-title><source>Eur. Heart J.</source><year>2008</year><volume>29</volume><fpage>2073</fpage><lpage>2082</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehn296</pub-id><pub-id pub-id-type="pmid">18617482</pub-id>
</element-citation></ref><ref id="B27-vaccines-12-01321"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>G.-L.</given-names></name>
<name><surname>Seon</surname><given-names>S.-H.</given-names></name>
<name><surname>Rhee</surname><given-names>D.-K.</given-names></name>
</person-group><article-title>Pneumonia and Streptococcus pneumoniae vaccine</article-title><source>Arch. Pharmacal Res.</source><year>2017</year><volume>40</volume><fpage>885</fpage><lpage>893</lpage><pub-id pub-id-type="doi">10.1007/s12272-017-0933-y</pub-id></element-citation></ref><ref id="B28-vaccines-12-01321"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alon</surname><given-names>D.</given-names></name>
<name><surname>Stein</surname><given-names>G.Y.</given-names></name>
<name><surname>Korenfeld</surname><given-names>R.</given-names></name>
<name><surname>Fuchs</surname><given-names>S.</given-names></name>
</person-group><article-title>Predictors and Outcomes of Infection-Related Hospital Admissions of Heart Failure Patients</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e72476</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0072476</pub-id><pub-id pub-id-type="pmid">24009684</pub-id>
</element-citation></ref><ref id="B29-vaccines-12-01321"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maire</surname><given-names>A.</given-names></name>
<name><surname>Chapet</surname><given-names>N.</given-names></name>
<name><surname>Aguilhon</surname><given-names>S.</given-names></name>
<name><surname>Laugier</surname><given-names>M.-L.</given-names></name>
<name><surname>Laffont-Lozes</surname><given-names>P.</given-names></name>
<name><surname>Rigoni</surname><given-names>M.</given-names></name>
<name><surname>Mathieu</surname><given-names>B.</given-names></name>
<name><surname>Audurier</surname><given-names>Y.</given-names></name>
<name><surname>Breuker</surname><given-names>C.</given-names></name>
<name><surname>de Barry</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Evaluation of vaccination coverage in heart failure patients in a tertiary center</article-title><source>Heliyon</source><year>2023</year><volume>9</volume><fpage>e18080</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2023.e18080</pub-id><pub-id pub-id-type="pmid">37519644</pub-id>
</element-citation></ref><ref id="B30-vaccines-12-01321"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hutchinson</surname><given-names>E.C.</given-names></name>
</person-group><article-title>Influenza Virus</article-title><source>Trends Microbiol.</source><year>2018</year><volume>26</volume><fpage>809</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2018.05.013</pub-id><pub-id pub-id-type="pmid">29909041</pub-id>
</element-citation></ref><ref id="B31-vaccines-12-01321"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shah</surname><given-names>S.A.W.</given-names></name>
<name><surname>Palomar</surname><given-names>D.P.</given-names></name>
<name><surname>Barr</surname><given-names>I.</given-names></name>
<name><surname>Poon</surname><given-names>L.L.M.</given-names></name>
<name><surname>Quadeer</surname><given-names>A.A.</given-names></name>
<name><surname>McKay</surname><given-names>M.R.</given-names></name>
</person-group><article-title>Seasonal antigenic prediction of influenza A H3N2 using machine learning</article-title><source>Nat. Commun.</source><year>2024</year><volume>15</volume><fpage>3833</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-47862-9</pub-id><pub-id pub-id-type="pmid">38714654</pub-id>
</element-citation></ref><ref id="B32-vaccines-12-01321"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Javanian</surname><given-names>M.</given-names></name>
<name><surname>Barary</surname><given-names>M.</given-names></name>
<name><surname>Ghebrehewet</surname><given-names>S.</given-names></name>
<name><surname>Koppolu</surname><given-names>V.</given-names></name>
<name><surname>Vasigala</surname><given-names>V.R.</given-names></name>
<name><surname>Ebrahimpour</surname><given-names>S.</given-names></name>
</person-group><article-title>A brief review of influenza virus infection</article-title><source>J. Med. Virol.</source><year>2021</year><volume>93</volume><fpage>4638</fpage><lpage>4646</lpage><pub-id pub-id-type="doi">10.1002/jmv.26990</pub-id><pub-id pub-id-type="pmid">33792930</pub-id>
</element-citation></ref><ref id="B33-vaccines-12-01321"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Panhwar</surname><given-names>M.S.</given-names></name>
<name><surname>Kalra</surname><given-names>A.</given-names></name>
<name><surname>Gupta</surname><given-names>T.</given-names></name>
<name><surname>Kolte</surname><given-names>D.</given-names></name>
<name><surname>Khera</surname><given-names>S.</given-names></name>
<name><surname>Bhatt</surname><given-names>D.L.</given-names></name>
<name><surname>Ginwalla</surname><given-names>M.</given-names></name>
</person-group><article-title>Effect of Influenza on Outcomes in Patients with Heart Failure</article-title><source>JACC Heart Fail.</source><year>2019</year><volume>7</volume><fpage>112</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.jchf.2018.10.011</pub-id><pub-id pub-id-type="pmid">30611718</pub-id>
</element-citation></ref><ref id="B34-vaccines-12-01321"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Loeb</surname><given-names>M.</given-names></name>
<name><surname>Roy</surname><given-names>A.</given-names></name>
<name><surname>Dokainish</surname><given-names>H.</given-names></name>
<name><surname>Dans</surname><given-names>A.</given-names></name>
<name><surname>Palileo-Villanueva</surname><given-names>L.M.</given-names></name>
<name><surname>Karaye</surname><given-names>K.</given-names></name>
<name><surname>Zhu</surname><given-names>J.</given-names></name>
<name><surname>Liang</surname><given-names>Y.</given-names></name>
<name><surname>Goma</surname><given-names>F.</given-names></name>
<name><surname>Damasceno</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Influenza vaccine to reduce adverse vascular events in patients with heart failure: A multinational randomised, double-blind, placebo-controlled trial</article-title><source>Lancet Glob. Health</source><year>2022</year><volume>10</volume><fpage>e1835</fpage><lpage>e1844</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(22)00432-6</pub-id><pub-id pub-id-type="pmid">36400089</pub-id>
</element-citation></ref><ref id="B35-vaccines-12-01321"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Poudel</surname><given-names>S.</given-names></name>
<name><surname>Shehadeh</surname><given-names>F.</given-names></name>
<name><surname>Zacharioudakis</surname><given-names>I.M.</given-names></name>
<name><surname>Tansarli</surname><given-names>G.S.</given-names></name>
<name><surname>Zervou</surname><given-names>F.N.</given-names></name>
<name><surname>Kalligeros</surname><given-names>M.</given-names></name>
<name><surname>van Aalst</surname><given-names>R.</given-names></name>
<name><surname>Chit</surname><given-names>A.</given-names></name>
<name><surname>Mylonakis</surname><given-names>E.</given-names></name>
</person-group><article-title>The Effect of Influenza Vaccination on Mortality and Risk of Hospitalization in Patients with Heart Failure: A Systematic Review and Meta-analysis</article-title><source>Open Forum Infect. Dis.</source><year>2019</year><volume>6</volume><fpage>ofz159</fpage><pub-id pub-id-type="doi">10.1093/ofid/ofz159</pub-id><pub-id pub-id-type="pmid">31041354</pub-id>
</element-citation></ref><ref id="B36-vaccines-12-01321"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Modin</surname><given-names>D.</given-names></name>
<name><surname>J&#x000f8;rgensen</surname><given-names>M.E.</given-names></name>
<name><surname>Gislason</surname><given-names>G.</given-names></name>
<name><surname>Jensen</surname><given-names>J.S.</given-names></name>
<name><surname>K&#x000f8;ber</surname><given-names>L.</given-names></name>
<name><surname>Claggett</surname><given-names>B.</given-names></name>
<name><surname>Hegde</surname><given-names>S.M.</given-names></name>
<name><surname>Solomon</surname><given-names>S.D.</given-names></name>
<name><surname>Torp-Pedersen</surname><given-names>C.</given-names></name>
<name><surname>Biering-S&#x000f8;rensen</surname><given-names>T.</given-names></name>
</person-group><article-title>Influenza Vaccine in Heart Failure</article-title><source>Circulation</source><year>2019</year><volume>139</volume><fpage>575</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.118.036788</pub-id><pub-id pub-id-type="pmid">30586760</pub-id>
</element-citation></ref><ref id="B37-vaccines-12-01321"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kopel</surname><given-names>E.</given-names></name>
<name><surname>Klempfner</surname><given-names>R.</given-names></name>
<name><surname>Goldenberg</surname><given-names>I.</given-names></name>
</person-group><article-title>Influenza vaccine and survival in acute heart failure</article-title><source>Eur. J. Heart Fail.</source><year>2014</year><volume>16</volume><fpage>264</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1002/ejhf.14</pub-id><pub-id pub-id-type="pmid">24464586</pub-id>
</element-citation></ref><ref id="B38-vaccines-12-01321"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gotsman</surname><given-names>I.</given-names></name>
<name><surname>Shuvy</surname><given-names>M.</given-names></name>
<name><surname>Tahiroglu</surname><given-names>I.</given-names></name>
<name><surname>Zwas</surname><given-names>D.R.</given-names></name>
<name><surname>Keren</surname><given-names>A.</given-names></name>
</person-group><article-title>Influenza Vaccination and Outcome in Heart Failure</article-title><source>Am. J. Cardiol.</source><year>2020</year><volume>128</volume><fpage>134</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2020.05.019</pub-id><pub-id pub-id-type="pmid">32650907</pub-id>
</element-citation></ref><ref id="B39-vaccines-12-01321"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vardeny</surname><given-names>O.</given-names></name>
<name><surname>Claggett</surname><given-names>B.</given-names></name>
<name><surname>Udell</surname><given-names>J.A.</given-names></name>
<name><surname>Packer</surname><given-names>M.</given-names></name>
<name><surname>Zile</surname><given-names>M.</given-names></name>
<name><surname>Rouleau</surname><given-names>J.</given-names></name>
<name><surname>Swedberg</surname><given-names>K.</given-names></name>
<name><surname>Desai</surname><given-names>A.S.</given-names></name>
<name><surname>Lefkowitz</surname><given-names>M.</given-names></name>
<name><surname>Shi</surname><given-names>V.</given-names></name>
<etal/>
</person-group><article-title>Influenza Vaccination in Patients with Chronic Heart Failure</article-title><source>JACC Heart Fail.</source><year>2015</year><volume>4</volume><fpage>152</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1016/j.jchf.2015.10.012</pub-id><pub-id pub-id-type="pmid">26746371</pub-id>
</element-citation></ref><ref id="B40-vaccines-12-01321"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>C.</given-names></name>
<name><surname>Sachdeva</surname><given-names>A.</given-names></name>
<name><surname>Khamar</surname><given-names>J.</given-names></name>
<name><surname>Bu</surname><given-names>C.</given-names></name>
<name><surname>Bartoszko</surname><given-names>J.</given-names></name>
<name><surname>Loeb</surname><given-names>M.</given-names></name>
</person-group><article-title>Effectiveness of the influenza vaccine at reducing adverse events in patients with heart failure: A systematic review and meta-analysis</article-title><source>Vaccine</source><year>2022</year><volume>40</volume><fpage>3433</fpage><lpage>3443</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2022.04.039</pub-id><pub-id pub-id-type="pmid">35562195</pub-id>
</element-citation></ref><ref id="B41-vaccines-12-01321"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vardeny</surname><given-names>O.</given-names></name>
<name><surname>Kim</surname><given-names>K.</given-names></name>
<name><surname>Udell</surname><given-names>J.A.</given-names></name>
<name><surname>Joseph</surname><given-names>J.</given-names></name>
<name><surname>Desai</surname><given-names>A.S.</given-names></name>
<name><surname>Farkouh</surname><given-names>M.E.</given-names></name>
<name><surname>Hegde</surname><given-names>S.M.</given-names></name>
<name><surname>Hernandez</surname><given-names>A.F.</given-names></name>
<name><surname>McGeer</surname><given-names>A.</given-names></name>
<name><surname>Talbot</surname><given-names>H.K.</given-names></name>
<etal/>
</person-group><article-title>Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients with High-risk Cardiovascular Disease</article-title><source>JAMA</source><year>2021</year><volume>325</volume><fpage>39</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.23649</pub-id><pub-id pub-id-type="pmid">33275134</pub-id>
</element-citation></ref><ref id="B42-vaccines-12-01321"><label>42.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>OECD</collab>
</person-group><article-title>&#x0201c;Influenza Vaccination Rates&#x0201d; (Indicator)</article-title><year>2024</year><comment>Available online: <ext-link xlink:href="https://www.oecd-ilibrary.org/social-issues-migration-health/influenza-vaccination-rates/indicator/english_e452582e-en" ext-link-type="uri">https://www.oecd-ilibrary.org/social-issues-migration-health/influenza-vaccination-rates/indicator/english_e452582e-en</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-09">(accessed on 9 November 2024)</date-in-citation><pub-id pub-id-type="doi">10.1787/e452582e-en</pub-id></element-citation></ref><ref id="B43-vaccines-12-01321"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kawai</surname><given-names>A.T.</given-names></name>
<name><surname>Li</surname><given-names>L.</given-names></name>
<name><surname>Kulldorff</surname><given-names>M.</given-names></name>
<name><surname>Vellozzi</surname><given-names>C.</given-names></name>
<name><surname>Weintraub</surname><given-names>E.</given-names></name>
<name><surname>Baxter</surname><given-names>R.</given-names></name>
<name><surname>Belongia</surname><given-names>E.A.</given-names></name>
<name><surname>Daley</surname><given-names>M.F.</given-names></name>
<name><surname>Jacobsen</surname><given-names>S.J.</given-names></name>
<name><surname>Naleway</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Absence of associations between influenza vaccines and increased risks of seizures, Guillain&#x02013;Barr&#x000e9; syndrome, encephalitis, or anaphylaxis in the 2012&#x02013;2013 season</article-title><source>Pharmacoepidemiol. Drug Saf.</source><year>2014</year><volume>23</volume><fpage>548</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1002/pds.3575</pub-id><pub-id pub-id-type="pmid">24497128</pub-id>
</element-citation></ref><ref id="B44-vaccines-12-01321"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sicras-Mainar</surname><given-names>A.</given-names></name>
<name><surname>Sicras-Navarro</surname><given-names>A.</given-names></name>
<name><surname>Palacios</surname><given-names>B.</given-names></name>
<name><surname>Varela</surname><given-names>L.</given-names></name>
<name><surname>Delgado</surname><given-names>J.F.</given-names></name>
</person-group><article-title>Delgado, Epidemiology and treatment of heart failure in Spain: The HF-PATHWAYS study</article-title><source>REC Interv. Cardiol.</source><year>2022</year><volume>75</volume><fpage>31</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.recesp.2020.09.014</pub-id></element-citation></ref><ref id="B45-vaccines-12-01321"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sekiya</surname><given-names>T.</given-names></name>
<name><surname>Ohno</surname><given-names>M.</given-names></name>
<name><surname>Nomura</surname><given-names>N.</given-names></name>
<name><surname>Handabile</surname><given-names>C.</given-names></name>
<name><surname>Shingai</surname><given-names>M.</given-names></name>
<name><surname>Jackson</surname><given-names>D.C.</given-names></name>
<name><surname>Brown</surname><given-names>L.E.</given-names></name>
<name><surname>Kida</surname><given-names>H.</given-names></name>
</person-group><article-title>Selecting and Using the Appropriate Influenza Vaccine for Each Individual</article-title><source>Viruses</source><year>2021</year><volume>13</volume><elocation-id>971</elocation-id><pub-id pub-id-type="doi">10.3390/v13060971</pub-id><pub-id pub-id-type="pmid">34073843</pub-id>
</element-citation></ref><ref id="B46-vaccines-12-01321"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Y&#x000fc;ce</surname><given-names>M.</given-names></name>
<name><surname>Filiztekin</surname><given-names>E.</given-names></name>
<name><surname>&#x000d6;zkaya</surname><given-names>K.G.</given-names></name>
</person-group><article-title>COVID-19 diagnosis&#x02014;A review of current methods</article-title><source>Biosens. Bioelectron.</source><year>2020</year><volume>172</volume><elocation-id>112752</elocation-id><pub-id pub-id-type="doi">10.1016/j.bios.2020.112752</pub-id><pub-id pub-id-type="pmid">33126180</pub-id>
</element-citation></ref><ref id="B47-vaccines-12-01321"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tali</surname><given-names>S.H.S.</given-names></name>
<name><surname>LeBlanc</surname><given-names>J.J.</given-names></name>
<name><surname>Sadiq</surname><given-names>Z.</given-names></name>
<name><surname>Oyewunmi</surname><given-names>O.D.</given-names></name>
<name><surname>Camargo</surname><given-names>C.</given-names></name>
<name><surname>Nikpour</surname><given-names>B.</given-names></name>
<name><surname>Armanfard</surname><given-names>N.</given-names></name>
<name><surname>Sagan</surname><given-names>S.M.</given-names></name>
<name><surname>Jahanshahi-Anbuhi</surname><given-names>S.</given-names></name>
</person-group><article-title>Tools and Techniques for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/COVID-19 Detection</article-title><source>Clin. Microbiol. Rev.</source><year>2021</year><volume>34</volume><fpage>10</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1128/cmr.00228-20</pub-id></element-citation></ref><ref id="B48-vaccines-12-01321"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bader</surname><given-names>F.</given-names></name>
<name><surname>Manla</surname><given-names>Y.</given-names></name>
<name><surname>Atallah</surname><given-names>B.</given-names></name>
<name><surname>Starling</surname><given-names>R.C.</given-names></name>
</person-group><article-title>Heart failure and COVID-19</article-title><source>Heart Fail. Rev.</source><year>2020</year><volume>26</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1007/s10741-020-10008-2</pub-id></element-citation></ref><ref id="B49-vaccines-12-01321"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Deswal</surname><given-names>A.</given-names></name>
<name><surname>Khalid</surname><given-names>U.</given-names></name>
</person-group><article-title>COVID-19 myocarditis and long-term heart failure sequelae</article-title><source>Curr. Opin. Cardiol.</source><year>2020</year><volume>36</volume><fpage>234</fpage><lpage>240</lpage><pub-id pub-id-type="doi">10.1097/HCO.0000000000000832</pub-id></element-citation></ref><ref id="B50-vaccines-12-01321"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Heidecker</surname><given-names>B.</given-names></name>
<name><surname>Dagan</surname><given-names>N.</given-names></name>
<name><surname>Balicer</surname><given-names>R.</given-names></name>
<name><surname>Eriksson</surname><given-names>U.</given-names></name>
<name><surname>Rosano</surname><given-names>G.</given-names></name>
<name><surname>Coats</surname><given-names>A.</given-names></name>
<name><surname>Tsch&#x000f6;pe</surname><given-names>C.</given-names></name>
<name><surname>Kelle</surname><given-names>S.</given-names></name>
<name><surname>Poland</surname><given-names>G.A.</given-names></name>
<name><surname>Frustaci</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Myocarditis following COVID-19 vaccine: Incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart Failure Association of the European Society of Cardiology (ESC) and the ESC Working Group on Myocardial and Pericardial Diseases</article-title><source>Eur. J. Heart Fail.</source><year>2022</year><volume>24</volume><fpage>2000</fpage><lpage>2018</lpage><pub-id pub-id-type="doi">10.1002/ejhf.2669</pub-id><pub-id pub-id-type="pmid">36065751</pub-id>
</element-citation></ref><ref id="B51-vaccines-12-01321"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Parenica</surname><given-names>J.</given-names></name>
<name><surname>Benesova</surname><given-names>K.</given-names></name>
<name><surname>Radvan</surname><given-names>M.</given-names></name>
<name><surname>Sanca</surname><given-names>O.</given-names></name>
<name><surname>Hlasensky</surname><given-names>J.</given-names></name>
<name><surname>Lokaj</surname><given-names>P.</given-names></name>
<name><surname>Ondrus</surname><given-names>T.</given-names></name>
<name><surname>Helanova</surname><given-names>K.</given-names></name>
<name><surname>Kala</surname><given-names>P.</given-names></name>
<name><surname>Dusek</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>COVID-19 vaccine booster significantly decreases the risk of intensive care unit hospitalization in heart failure patients during the Omicron variant wave: A population-based study</article-title><source>Front. Cardiovasc. Med.</source><year>2022</year><volume>9</volume><elocation-id>998842</elocation-id><pub-id pub-id-type="doi">10.3389/fcvm.2022.998842</pub-id><pub-id pub-id-type="pmid">36337877</pub-id>
</element-citation></ref><ref id="B52-vaccines-12-01321"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chilosi</surname><given-names>M.</given-names></name>
<name><surname>Doglioni</surname><given-names>C.</given-names></name>
<name><surname>Ravaglia</surname><given-names>C.</given-names></name>
<name><surname>Piciucchi</surname><given-names>S.</given-names></name>
<name><surname>Dubini</surname><given-names>A.</given-names></name>
<name><surname>Stefanizzi</surname><given-names>L.</given-names></name>
<name><surname>Poletti</surname><given-names>V.</given-names></name>
</person-group><article-title>COVID-19. Biology, pathophysiology, and immunology: A pathologist view</article-title><source>Pathologica</source><year>2023</year><volume>115</volume><fpage>248</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.32074/1591-951X-954</pub-id><pub-id pub-id-type="pmid">38054899</pub-id>
</element-citation></ref><ref id="B53-vaccines-12-01321"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Louis</surname><given-names>D.W.</given-names></name>
<name><surname>Louis</surname><given-names>D.W.</given-names></name>
<name><surname>Saad</surname><given-names>M.</given-names></name>
<name><surname>Saad</surname><given-names>M.</given-names></name>
<name><surname>Vijayakumar</surname><given-names>S.</given-names></name>
<name><surname>Vijayakumar</surname><given-names>S.</given-names></name>
<name><surname>Ilyas</surname><given-names>S.</given-names></name>
<name><surname>Ilyas</surname><given-names>S.</given-names></name>
<name><surname>Kokkirala</surname><given-names>A.</given-names></name>
<name><surname>Kokkirala</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>The Cardiovascular Manifestations of COVID-19</article-title><source>Cardiol. Clin.</source><year>2022</year><volume>40</volume><fpage>277</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1016/j.ccl.2022.03.001</pub-id><pub-id pub-id-type="pmid">35851451</pub-id>
</element-citation></ref><ref id="B54-vaccines-12-01321"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tadokoro</surname><given-names>T.</given-names></name>
<name><surname>Ohta-Ogo</surname><given-names>K.</given-names></name>
<name><surname>Ikeda</surname><given-names>Y.</given-names></name>
<name><surname>Sugiyama</surname><given-names>M.</given-names></name>
<name><surname>Katano</surname><given-names>H.</given-names></name>
<name><surname>Hatakeyama</surname><given-names>K.</given-names></name>
<name><surname>Matsumoto</surname><given-names>M.</given-names></name>
<name><surname>Tashiro</surname><given-names>H.</given-names></name>
</person-group><article-title>COVID-19-associated myocardial injury: A case report</article-title><source>ESC Heart Fail.</source><year>2023</year><volume>10</volume><fpage>1461</fpage><lpage>1466</lpage><pub-id pub-id-type="doi">10.1002/ehf2.14295</pub-id><pub-id pub-id-type="pmid">36691883</pub-id>
</element-citation></ref><ref id="B55-vaccines-12-01321"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Urban</surname><given-names>S.</given-names></name>
<name><surname>Fu&#x00142;ek</surname><given-names>M.</given-names></name>
<name><surname>B&#x00142;aziak</surname><given-names>M.</given-names></name>
<name><surname>Iwanek</surname><given-names>G.</given-names></name>
<name><surname>Jura</surname><given-names>M.</given-names></name>
<name><surname>Fu&#x00142;ek</surname><given-names>K.</given-names></name>
<name><surname>Guzik</surname><given-names>M.</given-names></name>
<name><surname>Garus</surname><given-names>M.</given-names></name>
<name><surname>Gajewski</surname><given-names>P.</given-names></name>
<name><surname>Lewandowski</surname><given-names>&#x00141;.</given-names></name>
<etal/>
</person-group><article-title>COVID-19 Related Myocarditis in Adults: A Systematic Review of Case Reports</article-title><source>J. Clin. Med.</source><year>2022</year><volume>11</volume><elocation-id>5519</elocation-id><pub-id pub-id-type="doi">10.3390/jcm11195519</pub-id><pub-id pub-id-type="pmid">36233389</pub-id>
</element-citation></ref><ref id="B56-vaccines-12-01321"><label>56.</label><element-citation publication-type="other"><person-group person-group-type="author">
<name><surname>Hulscher</surname><given-names>N.</given-names></name>
<name><surname>Hodkinson</surname><given-names>R.</given-names></name>
<name><surname>Makis</surname><given-names>W.</given-names></name>
<name><surname>McCullough</surname><given-names>P.A.</given-names></name>
</person-group><article-title>Autopsy findings in cases of fatal COVID-19 vaccine-induced myocarditis</article-title><source>ESC Heart Fail.</source><year>2024</year><comment>
<italic toggle="yes">Online ahead of print</italic>
</comment><pub-id pub-id-type="doi">10.1002/ehf2.14680</pub-id></element-citation></ref><ref id="B57-vaccines-12-01321"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gimeno</surname><given-names>J.R.</given-names></name>
<name><surname>Olivotto</surname><given-names>I.</given-names></name>
<name><surname>Rodr&#x000ed;guez</surname><given-names>A.I.</given-names></name>
<name><surname>Ho</surname><given-names>C.Y.</given-names></name>
<name><surname>Fern&#x000e1;ndez</surname><given-names>A.</given-names></name>
<name><surname>Quiroga</surname><given-names>A.</given-names></name>
<name><surname>Espinosa</surname><given-names>M.A.</given-names></name>
<name><surname>G&#x000f3;mez-Gonz&#x000e1;lez</surname><given-names>C.</given-names></name>
<name><surname>Robledo</surname><given-names>M.</given-names></name>
<name><surname>Tojal-Sierra</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: Results of an international multicentre registry</article-title><source>ESC Heart Fail.</source><year>2022</year><volume>9</volume><fpage>2189</fpage><lpage>2198</lpage><pub-id pub-id-type="doi">10.1002/ehf2.13964</pub-id><pub-id pub-id-type="pmid">36255281</pub-id>
</element-citation></ref><ref id="B58-vaccines-12-01321"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bengel</surname><given-names>C.P.</given-names></name>
<name><surname>Kacapor</surname><given-names>R.</given-names></name>
</person-group><article-title>A report of two cases of myocarditis following mRNA coronavirus disease 2019 vaccination</article-title><source>Eur. Heart J. Case Rep.</source><year>2022</year><volume>6</volume><fpage>ytac004</fpage><pub-id pub-id-type="doi">10.1093/ehjcr/ytac004</pub-id><pub-id pub-id-type="pmid">35169677</pub-id>
</element-citation></ref><ref id="B59-vaccines-12-01321"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Muhammadzai</surname><given-names>H.Z.U.</given-names></name>
<name><surname>Rosal</surname><given-names>N.</given-names></name>
<name><surname>Cheema</surname><given-names>M.A.</given-names></name>
<name><surname>Haas</surname><given-names>D.</given-names></name>
</person-group><article-title>Left ventricular outflow tract thrombus in a patient with COVID-19&#x02014;A ticking time bomb: A case report</article-title><source>Eur. Heart J. Case Rep.</source><year>2022</year><volume>6</volume><fpage>ytac191</fpage><pub-id pub-id-type="doi">10.1093/ehjcr/ytac191</pub-id><pub-id pub-id-type="pmid">35592751</pub-id>
</element-citation></ref><ref id="B60-vaccines-12-01321"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Valiton</surname><given-names>V.</given-names></name>
<name><surname>Bendjelid</surname><given-names>K.</given-names></name>
<name><surname>Pache</surname><given-names>J.-C.</given-names></name>
<name><surname>Roffi</surname><given-names>M.</given-names></name>
<name><surname>Meyer</surname><given-names>P.</given-names></name>
</person-group><article-title>Coronavirus disease 2019-associated coronary endotheliitis and thrombotic microangiopathy causing cardiogenic shock: A case report</article-title><source>Eur. Heart J. Case Rep.</source><year>2022</year><volume>6</volume><fpage>ytac061</fpage><pub-id pub-id-type="doi">10.1093/ehjcr/ytac061</pub-id><pub-id pub-id-type="pmid">35295732</pub-id>
</element-citation></ref><ref id="B61-vaccines-12-01321"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rey</surname><given-names>J.R.</given-names></name>
<name><surname>Caro-Cod&#x000f3;n</surname><given-names>J.</given-names></name>
<name><surname>Rosillo</surname><given-names>S.O.</given-names></name>
<name><surname>Iniesta</surname><given-names>&#x000c1;.M.</given-names></name>
<name><surname>Castrej&#x000f3;n-Castrej&#x000f3;n</surname><given-names>S.</given-names></name>
<name><surname>Marco-Clement</surname><given-names>I.</given-names></name>
<name><surname>Mart&#x000ed;n-Polo</surname><given-names>L.</given-names></name>
<name><surname>Merino-Argos</surname><given-names>C.R.</given-names></name>
<name><surname>Rodr&#x000ed;guez-Sotelo</surname><given-names>L.</given-names></name>
<name><surname>Garc&#x000ed;a-Veas</surname><given-names>J.M.</given-names></name>
<etal/>
</person-group><article-title>Heart failure in COVID-19 patients: Prevalence, incidence and prognostic implications</article-title><source>Eur. J. Heart Fail.</source><year>2020</year><volume>22</volume><fpage>2205</fpage><lpage>2215</lpage><pub-id pub-id-type="doi">10.1002/ejhf.1990</pub-id><pub-id pub-id-type="pmid">32833283</pub-id>
</element-citation></ref><ref id="B62-vaccines-12-01321"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cannat&#x000e0;</surname><given-names>A.</given-names></name>
<name><surname>Bromage</surname><given-names>D.I.</given-names></name>
<name><surname>Rind</surname><given-names>I.A.</given-names></name>
<name><surname>Gregorio</surname><given-names>C.</given-names></name>
<name><surname>Bannister</surname><given-names>C.</given-names></name>
<name><surname>Albarjas</surname><given-names>M.</given-names></name>
<name><surname>Piper</surname><given-names>S.</given-names></name>
<name><surname>Shah</surname><given-names>A.M.</given-names></name>
<name><surname>McDonagh</surname><given-names>T.A.</given-names></name>
</person-group><article-title>Temporal trends in decompensated heart failure and outcomes during COVID-19: A multisite report from heart failure referral centres in London</article-title><source>Eur. J. Heart Fail.</source><year>2020</year><volume>22</volume><fpage>2219</fpage><lpage>2224</lpage><pub-id pub-id-type="doi">10.1002/ejhf.1986</pub-id><pub-id pub-id-type="pmid">32809274</pub-id>
</element-citation></ref><ref id="B63-vaccines-12-01321"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>K&#x000f6;nig</surname><given-names>S.</given-names></name>
<name><surname>Hohenstein</surname><given-names>S.</given-names></name>
<name><surname>Meier-Hellmann</surname><given-names>A.</given-names></name>
<name><surname>Kuhlen</surname><given-names>R.</given-names></name>
<name><surname>Hindricks</surname><given-names>G.</given-names></name>
<name><surname>Bollmann</surname><given-names>A.</given-names></name>
<collab>Helios Hospitals, Germany</collab>
</person-group><article-title>In-hospital care in acute heart failure during the COVID-19 pandemic: Insights from the German-wide Helios hospital network</article-title><source>Eur. J. Heart Fail.</source><year>2020</year><volume>22</volume><fpage>2190</fpage><lpage>2201</lpage><pub-id pub-id-type="doi">10.1002/ejhf.2044</pub-id><pub-id pub-id-type="pmid">33135851</pub-id>
</element-citation></ref><ref id="B64-vaccines-12-01321"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Coats</surname><given-names>A.J.S.</given-names></name>
<name><surname>Zheng</surname><given-names>Z.</given-names></name>
<name><surname>Adamo</surname><given-names>M.</given-names></name>
<name><surname>Ambrosio</surname><given-names>G.</given-names></name>
<name><surname>Anker</surname><given-names>S.D.</given-names></name>
<name><surname>Butler</surname><given-names>J.</given-names></name>
<name><surname>Xu</surname><given-names>D.</given-names></name>
<name><surname>Mao</surname><given-names>J.</given-names></name>
<name><surname>Khan</surname><given-names>M.S.</given-names></name>
<etal/>
</person-group><article-title>Management of heart failure patients with COVID-19: A joint position paper of the Chinese Heart Failure Association &#x00026; National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology</article-title><source>Eur. J. Heart Fail.</source><year>2020</year><volume>22</volume><fpage>941</fpage><lpage>956</lpage><pub-id pub-id-type="doi">10.1002/ejhf.1915</pub-id><pub-id pub-id-type="pmid">32463543</pub-id>
</element-citation></ref><ref id="B65-vaccines-12-01321"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tomasoni</surname><given-names>D.</given-names></name>
<name><surname>Italia</surname><given-names>L.</given-names></name>
<name><surname>Adamo</surname><given-names>M.</given-names></name>
<name><surname>Inciardi</surname><given-names>R.M.</given-names></name>
<name><surname>Lombardi</surname><given-names>C.M.</given-names></name>
<name><surname>Solomon</surname><given-names>S.D.</given-names></name>
<name><surname>Metra</surname><given-names>M.</given-names></name>
</person-group><article-title>COVID-19 and heart failure: From infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease</article-title><source>Eur. J. Heart Fail.</source><year>2020</year><volume>22</volume><fpage>957</fpage><lpage>966</lpage><pub-id pub-id-type="doi">10.1002/ejhf.1871</pub-id><pub-id pub-id-type="pmid">32412156</pub-id>
</element-citation></ref><ref id="B66-vaccines-12-01321"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sokolski</surname><given-names>M.</given-names></name>
<name><surname>Gajewski</surname><given-names>P.</given-names></name>
<name><surname>Zymli&#x00144;ski</surname><given-names>R.</given-names></name>
<name><surname>Biegus</surname><given-names>J.</given-names></name>
<name><surname>Berg</surname><given-names>J.M.T.</given-names></name>
<name><surname>Bor</surname><given-names>W.</given-names></name>
<name><surname>Braunschweig</surname><given-names>F.</given-names></name>
<name><surname>Caldeira</surname><given-names>D.</given-names></name>
<name><surname>Cuculi</surname><given-names>F.</given-names></name>
<name><surname>D&#x02019;Elia</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on Acute Admissions at the Emergency and Cardiology Departments Across Europe</article-title><source>Am. J. Med.</source><year>2021</year><volume>134</volume><fpage>482</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1016/j.amjmed.2020.08.043</pub-id><pub-id pub-id-type="pmid">33010226</pub-id>
</element-citation></ref><ref id="B67-vaccines-12-01321"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gajewski</surname><given-names>P.</given-names></name>
<name><surname>B&#x00142;aziak</surname><given-names>M.</given-names></name>
<name><surname>Urban</surname><given-names>S.</given-names></name>
<name><surname>Garus</surname><given-names>M.</given-names></name>
<name><surname>Braunschweig</surname><given-names>F.</given-names></name>
<name><surname>Caldeira</surname><given-names>D.</given-names></name>
<name><surname>Gawor</surname><given-names>A.</given-names></name>
<name><surname>Greenwood</surname><given-names>J.P.</given-names></name>
<name><surname>Guzik</surname><given-names>M.</given-names></name>
<name><surname>Halfwerk</surname><given-names>F.R.</given-names></name>
<etal/>
</person-group><article-title>Sex-stratified patterns of emergency cardiovascular admissions prior and during the COVID-19 pandemic</article-title><source>Sci. Rep.</source><year>2023</year><volume>13</volume><elocation-id>17924</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-023-44400-3</pub-id><pub-id pub-id-type="pmid">37864029</pub-id>
</element-citation></ref><ref id="B68-vaccines-12-01321"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Szarfer</surname><given-names>J.L.</given-names></name>
<name><surname>Puente</surname><given-names>L.</given-names></name>
<name><surname>Bono</surname><given-names>L.</given-names></name>
<name><surname>Estrella</surname><given-names>M.L.</given-names></name>
<name><surname>Doppler</surname><given-names>E.</given-names></name>
<name><surname>Llobera</surname><given-names>M.N.</given-names></name>
<name><surname>Arce</surname><given-names>M.P.</given-names></name>
<name><surname>Borri</surname><given-names>K.A.</given-names></name>
<name><surname>Fiandesio</surname><given-names>M.E.</given-names></name>
<name><surname>Ferraris</surname><given-names>M.J.</given-names></name>
<etal/>
</person-group><article-title>Impact of a prolonged COVID-19 lockdown on patterns of admission, mortality and performance indicators in a cardiovascular intensive care unit</article-title><source>Int. J. Qual. Health Care</source><year>2021</year><volume>33</volume><fpage>mzab029</fpage><pub-id pub-id-type="doi">10.1093/intqhc/mzab029</pub-id><pub-id pub-id-type="pmid">33620065</pub-id>
</element-citation></ref><ref id="B69-vaccines-12-01321"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sindet-Pedersen</surname><given-names>C.</given-names></name>
<name><surname>Michalik</surname><given-names>F.</given-names></name>
<name><surname>Strange</surname><given-names>J.E.</given-names></name>
<name><surname>Christensen</surname><given-names>D.M.</given-names></name>
<name><surname>Nouhravesh</surname><given-names>N.</given-names></name>
<name><surname>Gerds</surname><given-names>T.A.</given-names></name>
<name><surname>Andersson</surname><given-names>C.</given-names></name>
<name><surname>Folke</surname><given-names>F.</given-names></name>
<name><surname>Biering-S&#x000f8;rensen</surname><given-names>T.</given-names></name>
<name><surname>Fosb&#x000f8;l</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Risk of Worsening Heart Failure and All-Cause Mortality Following COVID-19 Vaccination in Patients with Heart Failure: A Nationwide Real-World Safety Study</article-title><source>Circ. Heart Fail.</source><year>2023</year><volume>16</volume><fpage>e010617</fpage><pub-id pub-id-type="doi">10.1161/CIRCHEARTFAILURE.123.010617</pub-id><pub-id pub-id-type="pmid">37503624</pub-id>
</element-citation></ref><ref id="B70-vaccines-12-01321"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Block</surname><given-names>J.P.</given-names></name>
</person-group><article-title>Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination&#x02014;PCORnet, United States, January 2021&#x02013;January 2022</article-title><source>Mmwr-Morb. Mortal. Wkly. Rep.</source><year>2022</year><volume>71</volume><fpage>517</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.15585/mmwr.mm7114e1</pub-id><pub-id pub-id-type="pmid">35389977</pub-id>
</element-citation></ref><ref id="B71-vaccines-12-01321"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kimura</surname><given-names>M.</given-names></name>
<name><surname>Hashimoto</surname><given-names>T.</given-names></name>
<name><surname>Noda</surname><given-names>E.</given-names></name>
<name><surname>Ishikawa</surname><given-names>Y.</given-names></name>
<name><surname>Ishikita</surname><given-names>A.</given-names></name>
<name><surname>Fujino</surname><given-names>T.</given-names></name>
<name><surname>Matsushima</surname><given-names>S.</given-names></name>
<name><surname>Ide</surname><given-names>T.</given-names></name>
<name><surname>Kinugawa</surname><given-names>S.</given-names></name>
<name><surname>Nagaoka</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Fulminant necrotizing eosinophilic myocarditis after COVID-19 vaccination survived with mechanical circulatory support</article-title><source>ESC Heart Fail.</source><year>2022</year><volume>9</volume><fpage>2732</fpage><lpage>2737</lpage><pub-id pub-id-type="doi">10.1002/ehf2.13962</pub-id><pub-id pub-id-type="pmid">35616026</pub-id>
</element-citation></ref><ref id="B72-vaccines-12-01321"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Wei</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Jiang</surname><given-names>R.</given-names></name>
<name><surname>Tan</surname><given-names>Z.</given-names></name>
<name><surname>Ouyang</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Lei</surname><given-names>C.</given-names></name>
<name><surname>Liu</surname><given-names>H.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
</person-group><article-title>Cardiac involvement in patients recovering from Delta Variant of COVID-19: A prospective multi-parametric MRI study</article-title><source>ESC Heart Fail.</source><year>2022</year><volume>9</volume><fpage>2576</fpage><lpage>2584</lpage><pub-id pub-id-type="doi">10.1002/ehf2.13971</pub-id><pub-id pub-id-type="pmid">35560820</pub-id>
</element-citation></ref><ref id="B73-vaccines-12-01321"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ohnishi</surname><given-names>M.</given-names></name>
<name><surname>Tanaka</surname><given-names>Y.</given-names></name>
<name><surname>Nishida</surname><given-names>S.</given-names></name>
<name><surname>Sugimoto</surname><given-names>T.</given-names></name>
</person-group><article-title>Case report of acute myocarditis after administration of coronavirus disease 2019 vaccine in Japan</article-title><source>Eur. Heart J. Case Rep.</source><year>2022</year><volume>6</volume><fpage>ytab534</fpage><pub-id pub-id-type="doi">10.1093/ehjcr/ytab534</pub-id><pub-id pub-id-type="pmid">35075442</pub-id>
</element-citation></ref><ref id="B74-vaccines-12-01321"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Viani</surname><given-names>G.M.</given-names></name>
<name><surname>Pedrotti</surname><given-names>P.</given-names></name>
<name><surname>Seregni</surname><given-names>R.</given-names></name>
<name><surname>Antonio</surname><given-names>B.</given-names></name>
</person-group><article-title>Effusive&#x02013;constrictive pericarditis after the second dose of BNT162b2 vaccine (Comirnaty): A case report</article-title><source>Eur. Heart J. Case Rep.</source><year>2022</year><volume>6</volume><fpage>ytac012</fpage><pub-id pub-id-type="doi">10.1093/ehjcr/ytac012</pub-id><pub-id pub-id-type="pmid">35233481</pub-id>
</element-citation></ref><ref id="B75-vaccines-12-01321"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hrycek</surname><given-names>E.</given-names></name>
<name><surname>Walawska-Hrycek</surname><given-names>A.</given-names></name>
<name><surname>Milewski</surname><given-names>K.</given-names></name>
<name><surname>Nowakowski</surname><given-names>P.</given-names></name>
<name><surname>Buszman</surname><given-names>P.</given-names></name>
<name><surname>&#x0017b;urakowski</surname><given-names>A.</given-names></name>
</person-group><article-title>The Influence of SARS-CoV-2 Vaccination on the Mortality and Outcomes of Patients with Both Myocardial Infarction and COVID-19</article-title><source>Vaccines</source><year>2024</year><volume>12</volume><elocation-id>983</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines12090983</pub-id><pub-id pub-id-type="pmid">39340015</pub-id>
</element-citation></ref><ref id="B76-vaccines-12-01321"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Blasco</surname><given-names>A.</given-names></name>
<name><surname>Royuela</surname><given-names>A.</given-names></name>
<name><surname>Garc&#x000ed;a-G&#x000f3;mez</surname><given-names>S.</given-names></name>
<name><surname>G&#x000f3;mez-Lozano</surname><given-names>N.</given-names></name>
<name><surname>S&#x000e1;nchez-Arjona</surname><given-names>A.</given-names></name>
<name><surname>de la Fuente</surname><given-names>J.</given-names></name>
<name><surname>Anel</surname><given-names>J.</given-names></name>
<name><surname>S&#x000e1;nchez-Galarraga</surname><given-names>I.</given-names></name>
<name><surname>P&#x000e9;rez-Redondo</surname><given-names>M.</given-names></name>
<name><surname>Gonz&#x000e1;lez</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Association of SARS-CoV-2 immunoserology and vaccination status with myocardial infarction severity and outcome</article-title><source>Vaccine</source><year>2024</year><volume>42</volume><fpage>126305</fpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2024.126305</pub-id><pub-id pub-id-type="pmid">39244425</pub-id>
</element-citation></ref><ref id="B77-vaccines-12-01321"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barda</surname><given-names>N.</given-names></name>
<name><surname>Dagan</surname><given-names>N.</given-names></name>
<name><surname>Ben-Shlomo</surname><given-names>Y.</given-names></name>
<name><surname>Kepten</surname><given-names>E.</given-names></name>
<name><surname>Waxman</surname><given-names>J.</given-names></name>
<name><surname>Ohana</surname><given-names>R.</given-names></name>
<name><surname>Hern&#x000e1;n</surname><given-names>M.A.</given-names></name>
<name><surname>Lipsitch</surname><given-names>M.</given-names></name>
<name><surname>Kohane</surname><given-names>I.</given-names></name>
<name><surname>Netzer</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Safety of the BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Setting</article-title><source>N. Engl. J. Med.</source><year>2021</year><volume>385</volume><fpage>1078</fpage><lpage>1090</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2110475</pub-id><pub-id pub-id-type="pmid">34432976</pub-id>
</element-citation></ref><ref id="B78-vaccines-12-01321"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wahid</surname><given-names>M.</given-names></name>
<name><surname>Jawed</surname><given-names>A.</given-names></name>
<name><surname>Mandal</surname><given-names>R.K.</given-names></name>
<name><surname>Areeshi</surname><given-names>M.Y.</given-names></name>
<name><surname>El-Shall</surname><given-names>N.A.</given-names></name>
<name><surname>Mohapatra</surname><given-names>R.K.</given-names></name>
<name><surname>Tuli</surname><given-names>H.S.</given-names></name>
<name><surname>Dhama</surname><given-names>K.</given-names></name>
<name><surname>Pellicano</surname><given-names>R.</given-names></name>
<name><surname>Fagoonee</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Role of available COVID-19 vaccines in reducing deaths and perspective for next generation vaccines and therapies to counter emerging viral variants: An update</article-title><source>Minerva Medica</source><year>2023</year><volume>114</volume><fpage>683</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.23736/S0026-4806.23.08509-9</pub-id><pub-id pub-id-type="pmid">37293890</pub-id>
</element-citation></ref><ref id="B79-vaccines-12-01321"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>K.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Qin</surname><given-names>M.</given-names></name>
<name><surname>Gao</surname><given-names>Y.</given-names></name>
<name><surname>Luo</surname><given-names>N.</given-names></name>
<name><surname>Xie</surname><given-names>W.</given-names></name>
<name><surname>Zou</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Ma</surname><given-names>X.</given-names></name>
</person-group><article-title>A systematic review and meta-analysis of the effectiveness and safety of COVID-19 vaccination in older adults</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><elocation-id>1113156</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1113156</pub-id><pub-id pub-id-type="pmid">36936964</pub-id>
</element-citation></ref><ref id="B80-vaccines-12-01321"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Witberg</surname><given-names>G.</given-names></name>
<name><surname>Barda</surname><given-names>N.</given-names></name>
<name><surname>Hoss</surname><given-names>S.</given-names></name>
<name><surname>Richter</surname><given-names>I.</given-names></name>
<name><surname>Wiessman</surname><given-names>M.</given-names></name>
<name><surname>Aviv</surname><given-names>Y.</given-names></name>
<name><surname>Grinberg</surname><given-names>T.</given-names></name>
<name><surname>Auster</surname><given-names>O.</given-names></name>
<name><surname>Dagan</surname><given-names>N.</given-names></name>
<name><surname>Balicer</surname><given-names>R.D.</given-names></name>
<etal/>
</person-group><article-title>Myocarditis after COVID-19 vaccination in a large health care organization</article-title><source>N. Engl. J. Med.</source><year>2021</year><volume>385</volume><fpage>2132</fpage><lpage>2139</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2110737</pub-id><pub-id pub-id-type="pmid">34614329</pub-id>
</element-citation></ref><ref id="B81-vaccines-12-01321"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oster</surname><given-names>M.E.</given-names></name>
<name><surname>Shay</surname><given-names>D.K.</given-names></name>
<name><surname>Su</surname><given-names>J.R.</given-names></name>
<name><surname>Gee</surname><given-names>J.</given-names></name>
<name><surname>Creech</surname><given-names>C.B.</given-names></name>
<name><surname>Broder</surname><given-names>K.R.</given-names></name>
<name><surname>Edwards</surname><given-names>K.</given-names></name>
<name><surname>Soslow</surname><given-names>J.H.</given-names></name>
<name><surname>Dendy</surname><given-names>J.M.</given-names></name>
<name><surname>Schlaudecker</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021</article-title><source>JAMA</source><year>2022</year><volume>327</volume><fpage>331</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.24110</pub-id><pub-id pub-id-type="pmid">35076665</pub-id>
</element-citation></ref><ref id="B82-vaccines-12-01321"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>van Kammen</surname><given-names>M.S.</given-names></name>
<name><surname>de Sousa</surname><given-names>D.A.</given-names></name>
<name><surname>Poli</surname><given-names>S.</given-names></name>
<name><surname>Cordonnier</surname><given-names>C.</given-names></name>
<name><surname>Heldner</surname><given-names>M.R.</given-names></name>
<name><surname>van de Munckhof</surname><given-names>A.</given-names></name>
<name><surname>Krzywicka</surname><given-names>K.</given-names></name>
<name><surname>van Haaps</surname><given-names>T.</given-names></name>
<name><surname>Ciccone</surname><given-names>A.</given-names></name>
<name><surname>Middeldorp</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Characteristics and Outcomes of Patients with Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine&#x02013;Induced Immune Thrombotic Thrombocytopenia</article-title><source>JAMA Neurol.</source><year>2021</year><volume>78</volume><fpage>1314</fpage><lpage>1323</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2021.3619</pub-id><pub-id pub-id-type="pmid">34581763</pub-id>
</element-citation></ref><ref id="B83-vaccines-12-01321"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Santosa</surname><given-names>A.</given-names></name>
<name><surname>Wettermark</surname><given-names>B.</given-names></name>
<name><surname>Fall</surname><given-names>T.</given-names></name>
<name><surname>Bj&#x000f6;rk</surname><given-names>J.</given-names></name>
<name><surname>B&#x000f6;rjesson</surname><given-names>M.</given-names></name>
<name><surname>Gissl&#x000e9;n</surname><given-names>M.</given-names></name>
<name><surname>Nyberg</surname><given-names>F.</given-names></name>
</person-group><article-title>Cardiovascular events following coronavirus disease 2019 vaccination in adults: A nationwide Swedish study</article-title><source>Eur. Heart J.</source><year>2024</year><fpage>ehae639</fpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehae639</pub-id><pub-id pub-id-type="pmid">39344920</pub-id>
</element-citation></ref><ref id="B84-vaccines-12-01321"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Briles</surname><given-names>D.E.</given-names></name>
<name><surname>Paton</surname><given-names>J.C.</given-names></name>
<name><surname>Mukerji</surname><given-names>R.</given-names></name>
<name><surname>Swiatlo</surname><given-names>E.</given-names></name>
<name><surname>Crain</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Pneumococcal Vaccines</article-title><source>Microbiol. Spectr.</source><year>2019</year><volume>7</volume><fpage>362</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1128/microbiolspec.GPP3-0028-2018</pub-id><pub-id pub-id-type="pmid">31858954</pub-id>
</element-citation></ref><ref id="B85-vaccines-12-01321"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Corrales-Medina</surname><given-names>V.F.</given-names></name>
<name><surname>Alvarez</surname><given-names>K.N.</given-names></name>
<name><surname>Weissfeld</surname><given-names>L.A.</given-names></name>
<name><surname>Angus</surname><given-names>D.C.</given-names></name>
<name><surname>Chirinos</surname><given-names>J.A.</given-names></name>
<name><surname>Chang</surname><given-names>C.-C.H.</given-names></name>
<name><surname>Newman</surname><given-names>A.</given-names></name>
<name><surname>Loehr</surname><given-names>L.</given-names></name>
<name><surname>Folsom</surname><given-names>A.R.</given-names></name>
<name><surname>Elkind</surname><given-names>M.S.</given-names></name>
<etal/>
</person-group><article-title>Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease</article-title><source>JAMA</source><year>2015</year><volume>313</volume><fpage>264</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1001/jama.2014.18229</pub-id><pub-id pub-id-type="pmid">25602997</pub-id>
</element-citation></ref><ref id="B86-vaccines-12-01321"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Violi</surname><given-names>F.</given-names></name>
<name><surname>Cangemi</surname><given-names>R.</given-names></name>
<name><surname>Falcone</surname><given-names>M.</given-names></name>
<name><surname>Taliani</surname><given-names>G.</given-names></name>
<name><surname>Pieralli</surname><given-names>F.</given-names></name>
<name><surname>Vannucchi</surname><given-names>V.</given-names></name>
<name><surname>Nozzoli</surname><given-names>C.</given-names></name>
<name><surname>Venditti</surname><given-names>M.</given-names></name>
<name><surname>Chirinos</surname><given-names>J.A.</given-names></name>
<name><surname>Corrales-Medina</surname><given-names>V.F.</given-names></name>
</person-group><article-title>SIXTUS (Thrombosis-Related Extrapulmonary Outcomes in Pneumonia) Study Group. Cardio- vascular complications and short-term mortality risk in communi- ty-acquired pneumonia</article-title><source>Clin. Infect. Dis.</source><year>2017</year><volume>64</volume><fpage>1486</fpage><lpage>1493</lpage><pub-id pub-id-type="doi">10.1093/cid/cix164</pub-id><pub-id pub-id-type="pmid">28205683</pub-id>
</element-citation></ref><ref id="B87-vaccines-12-01321"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ciszewski</surname><given-names>A.</given-names></name>
</person-group><article-title>Cardioprotective effect of influenza and pneumococcal vaccination in patients with cardiovascular diseases</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><fpage>202</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.11.078</pub-id><pub-id pub-id-type="pmid">29221893</pub-id>
</element-citation></ref><ref id="B88-vaccines-12-01321"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marra</surname><given-names>F.</given-names></name>
<name><surname>Zhang</surname><given-names>A.</given-names></name>
<name><surname>Gillman</surname><given-names>E.</given-names></name>
<name><surname>Bessai</surname><given-names>K.</given-names></name>
<name><surname>Parhar</surname><given-names>K.</given-names></name>
<name><surname>Vadlamudi</surname><given-names>N.K.</given-names></name>
</person-group><article-title>The protective effect of pneumococcal vaccination on cardiovascular disease in adults: A systematic review and meta-analysis</article-title><source>Int. J. Infect. Dis.</source><year>2020</year><volume>99</volume><fpage>204</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2020.07.038</pub-id><pub-id pub-id-type="pmid">32735953</pub-id>
</element-citation></ref><ref id="B89-vaccines-12-01321"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Antunes</surname><given-names>M.M.</given-names></name>
<name><surname>Duarte</surname><given-names>G.S.</given-names></name>
<name><surname>Brito</surname><given-names>D.</given-names></name>
<name><surname>Borges</surname><given-names>M.</given-names></name>
<name><surname>Costa</surname><given-names>J.</given-names></name>
<name><surname>Ferreira</surname><given-names>J.J.</given-names></name>
<name><surname>Pinto</surname><given-names>F.J.</given-names></name>
<name><surname>Caldeira</surname><given-names>D.</given-names></name>
</person-group><article-title>Pneumococcal vaccination in adults at very high risk or with established cardiovascular disease: Systematic review and meta-analysis</article-title><source>Eur. Heart J. Qual. Care Clin. Outcomes</source><year>2020</year><volume>7</volume><fpage>97</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1093/ehjqcco/qcaa030</pub-id></element-citation></ref><ref id="B90-vaccines-12-01321"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bhatt</surname><given-names>A.S.</given-names></name>
<name><surname>Liang</surname><given-names>L.</given-names></name>
<name><surname>DeVore</surname><given-names>A.D.</given-names></name>
<name><surname>Fonarow</surname><given-names>G.C.</given-names></name>
<name><surname>Solomon</surname><given-names>S.D.</given-names></name>
<name><surname>Vardeny</surname><given-names>O.</given-names></name>
<name><surname>Yancy</surname><given-names>C.W.</given-names></name>
<name><surname>Mentz</surname><given-names>R.J.</given-names></name>
<name><surname>Khariton</surname><given-names>Y.</given-names></name>
<name><surname>Chan</surname><given-names>P.S.</given-names></name>
<etal/>
</person-group><article-title>Hernandez&#x02014;Vaccination Trends in Patients with Heart Failure: Insights from Get with The Guidelines</article-title><source>JACC Heart Fail.</source><year>2018</year><volume>6</volume><fpage>844</fpage><lpage>855</lpage><pub-id pub-id-type="doi">10.1016/j.jchf.2018.04.012</pub-id><pub-id pub-id-type="pmid">30098960</pub-id>
</element-citation></ref><ref id="B91-vaccines-12-01321"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Musher</surname><given-names>D.M.</given-names></name>
<name><surname>Manoff</surname><given-names>S.B.</given-names></name>
<name><surname>Liss</surname><given-names>C.</given-names></name>
<name><surname>McFetridge</surname><given-names>R.D.</given-names></name>
<name><surname>Marchese</surname><given-names>R.D.</given-names></name>
<name><surname>Bushnell</surname><given-names>B.</given-names></name>
<name><surname>Alvarez</surname><given-names>F.</given-names></name>
<name><surname>Painter</surname><given-names>C.</given-names></name>
<name><surname>Blum</surname><given-names>M.D.</given-names></name>
<name><surname>Silber</surname><given-names>J.L.</given-names></name>
</person-group><article-title>Safety and Antibody Response, Including Antibody Persistence for 5 Years, after Primary Vaccination or Revaccination with Pneumococcal Polysaccharide Vaccine in Middle-Aged and Older Adults</article-title><source>J. Infect. Dis.</source><year>2010</year><volume>201</volume><fpage>516</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1086/649839</pub-id><pub-id pub-id-type="pmid">20092407</pub-id>
</element-citation></ref><ref id="B92-vaccines-12-01321"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tseng</surname><given-names>H.F.</given-names></name>
<name><surname>Sy</surname><given-names>L.S.</given-names></name>
<name><surname>Qian</surname><given-names>L.</given-names></name>
<name><surname>A Liu</surname><given-names>I.-L.</given-names></name>
<name><surname>Mercado</surname><given-names>C.</given-names></name>
<name><surname>Lewin</surname><given-names>B.</given-names></name>
<name><surname>Tartof</surname><given-names>S.Y.</given-names></name>
<name><surname>Nelson</surname><given-names>J.</given-names></name>
<name><surname>A Jackson</surname><given-names>L.</given-names></name>
<name><surname>Daley</surname><given-names>M.F.</given-names></name>
<etal/>
</person-group><article-title>Pneumococcal Conjugate Vaccine Safety in Elderly Adults</article-title><source>Open Forum Infect. Dis.</source><year>2018</year><volume>5</volume><fpage>ofy100</fpage><pub-id pub-id-type="doi">10.1093/ofid/ofy100</pub-id><pub-id pub-id-type="pmid">29977960</pub-id>
</element-citation></ref><ref id="B93-vaccines-12-01321"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marra</surname><given-names>F.</given-names></name>
<name><surname>Vadlamudi</surname><given-names>N.K.</given-names></name>
</person-group><article-title>Efficacy and Safety of the Pneumococcal Conjugate-13 Valent Vaccine in Adults</article-title><source>Aging Dis.</source><year>2019</year><volume>10</volume><fpage>404</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.14336/AD.2018.0512</pub-id><pub-id pub-id-type="pmid">31011485</pub-id>
</element-citation></ref><ref id="B94-vaccines-12-01321"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Falsey</surname><given-names>A.R.</given-names></name>
<name><surname>Hennessey</surname><given-names>P.A.</given-names></name>
<name><surname>Formica</surname><given-names>M.A.</given-names></name>
<name><surname>Cox</surname><given-names>C.</given-names></name>
<name><surname>Walsh</surname><given-names>E.E.</given-names></name>
</person-group><article-title>Respiratory Syncytial Virus Infection in Elderly and High-Risk Adults</article-title><source>N. Engl. J. Med.</source><year>2005</year><volume>352</volume><fpage>1749</fpage><lpage>1759</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa043951</pub-id><pub-id pub-id-type="pmid">15858184</pub-id>
</element-citation></ref><ref id="B95-vaccines-12-01321"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Woodruff</surname><given-names>R.C.</given-names></name>
<name><surname>Melgar</surname><given-names>M.</given-names></name>
<name><surname>Pham</surname><given-names>H.</given-names></name>
<name><surname>Sperling</surname><given-names>L.S.</given-names></name>
<name><surname>Loustalot</surname><given-names>F.</given-names></name>
<name><surname>Kirley</surname><given-names>P.D.</given-names></name>
<name><surname>Austin</surname><given-names>E.</given-names></name>
<name><surname>Yousey-Hindes</surname><given-names>K.</given-names></name>
<name><surname>Openo</surname><given-names>K.P.</given-names></name>
<name><surname>Ryan</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Acute Cardiac Events in Hospitalized Older Adults with Respiratory Syncytial Virus Infection</article-title><source>JAMA Intern. Med.</source><year>2024</year><volume>184</volume><fpage>602</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2024.0212</pub-id><pub-id pub-id-type="pmid">38619857</pub-id>
</element-citation></ref><ref id="B96-vaccines-12-01321"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Anderson</surname><given-names>E.J.</given-names></name>
<name><surname>Tippett</surname><given-names>A.</given-names></name>
<name><surname>Begier</surname><given-names>E.</given-names></name>
<name><surname>Gibson</surname><given-names>T.</given-names></name>
<name><surname>Ess</surname><given-names>G.</given-names></name>
<name><surname>Patel</surname><given-names>V.</given-names></name>
<name><surname>Taylor</surname><given-names>M.</given-names></name>
<name><surname>Reese</surname><given-names>O.</given-names></name>
<name><surname>Salazar</surname><given-names>L.</given-names></name>
<name><surname>Jadhao</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Relative Contribution of Diagnostic Testing to the Diagnosis of Respiratory Syncytial Virus in Hospitalized Adults in the United States</article-title><source>J. Infect. Dis.</source><year>2024</year><fpage>jiae346</fpage><pub-id pub-id-type="doi">10.1093/infdis/jiae346</pub-id></element-citation></ref><ref id="B97-vaccines-12-01321"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ivey</surname><given-names>K.S.</given-names></name>
<name><surname>Edwards</surname><given-names>K.M.</given-names></name>
<name><surname>Talbot</surname><given-names>H.K.</given-names></name>
</person-group><article-title>Respiratory Syncytial Virus and Associations with Cardiovascular Disease in Adults</article-title><source>Circ.</source><year>2018</year><volume>71</volume><fpage>1574</fpage><lpage>1583</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2018.02.013</pub-id></element-citation></ref><ref id="B98-vaccines-12-01321"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Loubet</surname><given-names>P.</given-names></name>
<name><surname>Lenzi</surname><given-names>N.</given-names></name>
<name><surname>Valette</surname><given-names>M.</given-names></name>
<name><surname>Foulongne</surname><given-names>V.</given-names></name>
<name><surname>Krivine</surname><given-names>A.</given-names></name>
<name><surname>Houhou</surname><given-names>N.</given-names></name>
<name><surname>Lagathu</surname><given-names>G.</given-names></name>
<name><surname>Rogez</surname><given-names>S.</given-names></name>
<name><surname>Alain</surname><given-names>S.</given-names></name>
<name><surname>Duval</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>Clinical characteristics and outcome of respiratory syncytial virus infection among adults hospitalized with influenza-like illness in France</article-title><source>Clin. Microbiol. Infect.</source><year>2016</year><volume>23</volume><fpage>253</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2016.11.014</pub-id><pub-id pub-id-type="pmid">27903461</pub-id>
</element-citation></ref><ref id="B99-vaccines-12-01321"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Biegus</surname><given-names>J.</given-names></name>
<name><surname>Szenborn</surname><given-names>L.</given-names></name>
<name><surname>Zymli&#x00144;ski</surname><given-names>R.</given-names></name>
<name><surname>Zakliczy&#x00144;ski</surname><given-names>M.</given-names></name>
<name><surname>Reczuch</surname><given-names>K.</given-names></name>
<name><surname>Guzik</surname><given-names>M.</given-names></name>
<name><surname>Urban</surname><given-names>S.</given-names></name>
<name><surname>Rosiek-Biegus</surname><given-names>M.</given-names></name>
<name><surname>Jankowiak</surname><given-names>B.</given-names></name>
<name><surname>Iwanek</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>The early safety profile of simultaneous vaccination against influenza and Respiratory Syncytial Virus (RSV) in patients with high-risk heart failure</article-title><source>Vaccine</source><year>2024</year><volume>42</volume><fpage>2937</fpage><lpage>2940</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2024.03.060</pub-id><pub-id pub-id-type="pmid">38531725</pub-id>
</element-citation></ref></ref-list></back><floats-group><table-wrap position="float" id="vaccines-12-01321-t001"><object-id pub-id-type="pii">vaccines-12-01321-t001_Table 1</object-id><label>Table 1</label><caption><p>Impact of individual vaccines in HF populations on selected outcomes.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Index</bold>
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Study</bold>
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Vaccine</bold>
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Number of Patients</bold>
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Outcome</bold>
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Hazard Ratio (95% CI)</bold>
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold><italic toggle="yes">p</italic>-Value</bold>
</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Loeb et al. [<xref rid="B34-vaccines-12-01321" ref-type="bibr">34</xref>]</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Influenza</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">2560 vaccinated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Death-all cause</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.90 (0.79&#x02013;1.03)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.13</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Death-cardiovascular</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.89 (0.77&#x02013;1.04)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.13</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hospitalization for heart failure</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.88 (0.74&#x02013;1.05)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.15</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pneumonia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.58 (0.42&#x02013;0.80)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0006</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">2</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Poudel et al. [<xref rid="B35-vaccines-12-01321" ref-type="bibr">35</xref>]</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Influenza</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">82,354</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Death-all cause </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.69 (0.51&#x02013;0.87)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not included</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hospitalization for heart failure </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.62 (0.00&#x02013;1.23)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not included</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">3</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Modin et al. [<xref rid="B36-vaccines-12-01321" ref-type="bibr">36</xref>]</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Influenza</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">134,048</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Death-all cause</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.82 (0.81&#x02013;0.84)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Death- cardiovascular</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.82 (0.81&#x02013;0.84)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hospitalization due to influenza or pneumonia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.96 (0.93&#x02013;0.98)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.002</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">4</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Kopel et al. [<xref rid="B37-vaccines-12-01321" ref-type="bibr">37</xref>]</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Influenza</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1964 (501 vaccinated)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In-hospital mortality</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.71 (0.42&#x02013;1.18)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.19</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1-year mortality</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.81 (0.66&#x02013;0.99)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.04</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4-year mortality</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.83 (0.73&#x02013;0.95)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.006</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vardeny et al. [<xref rid="B38-vaccines-12-01321" ref-type="bibr">38</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8099 (1769 vaccinated)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All-cause death </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.81 (0.67&#x02013;0.97)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.015</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">6</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Gotsman et al. [<xref rid="B39-vaccines-12-01321" ref-type="bibr">39</xref>]</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Influenza </td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">6435 (4440 vaccinated)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All-cause mortality</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.77 (0.65&#x02013;0.91)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.01</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Death and cardiovascular hospitalizations</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.83 (0.76&#x02013;0.90)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bhatt et al. [<xref rid="B40-vaccines-12-01321" ref-type="bibr">40</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pneumococcal infection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">313,761</td><td colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Pneumococcal vaccination does not affect the clinical outcomes of HF patients</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Index</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Study</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Vaccine</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Number of Patients</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Effect</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Risk Ratio (95% CI)</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold><italic toggle="yes">p</italic>-Value</bold>
</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">8</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Gupta et al. [<xref rid="B41-vaccines-12-01321" ref-type="bibr">41</xref>]</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Influenza</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">247,842</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All-cause mortality</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.75 (0.71&#x02013;0.79)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cardiovascular-related mortality</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.77 (0.73&#x02013;0.81)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All-cause hospitalization</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.24 (1.13&#x02013;1.35)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Index</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Study</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Vaccine</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Number of Patients</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Effect</bold>
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Risk Difference (95% CI)</bold>
</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">9</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Sinder-Pedersen et al. [<xref rid="B42-vaccines-12-01321" ref-type="bibr">42</xref>]</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">COVID-19</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">101,786 (50,893 vaccinated)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90-day risk all-cause death</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">&#x02212;0.33% (&#x02212;0.81% to &#x02212;0.49%) with an advantage for vaccinated</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90-day risk in-hospital admission for HF</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">0.02% (&#x02212;0.11% to 0.15%) with an advantage for not vaccinated</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90-day risk of venous thromboembolism</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">&#x02212;0.02% (&#x02212;0.05% to 0.01%) with an advantage for vaccinated</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90-day risk pneumonia</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">&#x02212;0.64% (&#x02212;0.81 to 0.49%) with an advantage for vaccinated</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vaccines-12-01321-t002"><object-id pub-id-type="pii">vaccines-12-01321-t002_Table 2</object-id><label>Table 2</label><caption><p>Influenza vaccination coverage in specific countries.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Trial/Source</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Country</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Year</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccination</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">65 Years or over Vaccinated HF Population (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Total Vaccinated HF Population (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical Trial Vaccinated Population (%)</th></tr></thead><tbody><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">OECD Health Statistics 2024 [<xref rid="B43-vaccines-12-01321" ref-type="bibr">43</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Poland</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2022</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Germany</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2022</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">France</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2023</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Czech Republic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2023</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Norway</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2023</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">64.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2023</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Poland</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2023</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Influenza</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">The PARADIGM-HF Trial&#x02014;Vardeny et al. [<xref rid="B38-vaccines-12-01321" ref-type="bibr">38</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Netherlands</td><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">2016</td><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Influenza</td><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">-</td><td rowspan="8" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">77.5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Great Britain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">77.2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Belgium</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67.5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Asia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.6</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">North America </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52.8</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Poland</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.6</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">United States</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55.1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sweden</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55.2</td></tr></tbody></table></table-wrap></floats-group></article>